mayo

2026

Revisado: 16 de julio de 2026

En forma, rápido y casi muerto: cómo un ciclista de clase mundial descubrió una enfermedad cardíaca silenciosa

Cómo utilizar este artículo

Aviso médico: Este artículo tiene fines exclusivamente educativos y no constituye un consejo médico. Consulte siempre a su médico para obtener orientación personalizada.

Lectura fácil

El gancho: El secreto oculto a simple vista

Imagina un auto deportivo de alta gama. Es elegante, brillante y está construido para ganar las carreras más difíciles. Por fuera, se ve perfecto. La gente se detiene a mirar cuando pasa porque parece que pudiera alcanzar las 200 millas por hora. Pero muy dentro del motor, hay un problema oculto. La línea de combustible —el tubo que lleva la gasolina al motor— está casi completamente tapada con mugre. El auto aún puede andar, pero no puede alcanzar su velocidad máxima. Si esa mugre sigue acumulándose, el motor eventualmente dejará de funcionar por completo.

Esto es exactamente lo que le sucedió al Dr. Peter Megdal. En 2014, Peter era un ciclista de élite de 55 años. Estaba en la cima de su carrera, estableciendo récords nacionales y sintiéndose “invencible”. Pasaba de seis a diez horas cada semana entrenando su cuerpo para ser una máquina. Por fuera, era el retrato de la salud perfecta. Pero su corazón estaba fallando en secreto.

A pesar de ser un atleta de talla mundial, Peter tenía una acumulación peligrosa de mugre en sus arterias. Esta mugre se llama placa, y conduce a enfermedades cardíacas. La mayoría de las personas cree que si estás en forma y haces ejercicio, estás a salvo. La historia de Peter demuestra que estar en forma no significa que seas inmune a los problemas cardíacos. Tu cuerpo puede parecer un coche deportivo por fuera mientras que las “líneas de combustible” por dentro se están cerrando.

Conclusión 1: Tu mejor señal de advertencia no es el dolor en el pecho, sino tu “medidor de potencia”

La mayoría de las personas piensa que un problema cardíaco siempre viene acompañado de un dolor agudo y opresivo en el pecho. Pero para las personas que son muy activas, ese dolor a menudo permanece oculto. Los médicos llaman a esto “isquemia silenciosa”(lo cual es una forma elegante de decir que tu corazón no está recibiendo suficiente sangre, pero no puedes sentirlo).

Peter notó que algo andaba mal, pero no era dolor. Era su“medidor de potencia.” Como ciclista de competencia, llevó un registro exacto de cuánta potencia podían generar sus piernas. A lo largo de dos años, notó una disminución de 14% en su potencia. No se estaba volviendo más lento porque fuera perezoso o porque se estuviera haciendo mayor. Se estaba volviendo más lento porque su corazón no podía llevar suficiente sangre a sus músculos para que siguieran trabajando a toda velocidad.

¿Por qué no sintió dolor? La respuesta es “hipoalgesia inducida por el ejercicio”) (lo cual es la forma en que el cuerpo utiliza el ejercicio como un analgésico natural). Cuando te ejercitas duro, tu cuerpo libera sustancias químicas que adormecen el dolor para que puedas seguir adelante. Esto es excelente para terminar una carrera, pero es peligroso para detectar un problema cardíaco. Además, los atletas suelen tener una “circulación colateral robusta”. Esto significa que sus cuerpos son tan atléticos que en realidad desarrollan pequeños “tubos de respaldo” para mover la sangre alrededor de una obstrucción.

“La combinación de hipoalgesia inducida por el ejercicio, alta reserva cardiorrespiratoria y abundante circulación colateral puede enmascarar la isquemia hasta la carga de trabajo máxima, retrasando el diagnóstico.”

En palabras sencillas, tu cuerpo es tan bueno para resolver problemas que no sabrás que hay una “tubería tapada” hasta que intentes ir a toda velocidad. Para las personas activas, una caída en el rendimiento —como no poder correr tan rápido o levantar tanto peso— suele ser la única señal de advertencia que recibirás.

Conclusión 2: Uno de cada cinco ataques cardíacos es un “fantasma”

Las enfermedades cardíacas son la principal causa de muerte en el mundo, y las cifras son verdaderamente descomunales. En Estados Unidos, la salud del corazón no es solo un problema personal; es una crisis nacional que ocurre cada minuto de cada día.

La salud del corazón en cifras:

40 segundos: Con qué frecuencia alguien en los EE. UU. tiene un infarto cardíaco.
36 segundos: Con qué frecuencia muere alguien de una enfermedad cardíaca.
655,000: El número de estadounidenses que mueren por enfermedad cardíaca cada año.
805,000: El número total de ataques cardíacos en EE. UU. cada año.
795,000: El número de personas que sufren un derrame cerebral todos los años.
401: El número de personas que mueren a causa de un derrame cerebral todos los días.

Tal vez el hecho más aterrador es que muchas personas ni siquiera saben que están teniendo un ataque cardíaco. Aproximadamente 1 de cada 5 ataques cardíacos es “silencioso”.” Estos son como ataques “fantasma”. El daño al músculo cardíaco ocurre, pero la persona nunca siente los síntomas típicos como presión en el pecho o taquicardia. Continúan con su día, preparando la cena o viendo la televisión, mientras su corazón lucha por sobrevivir. Por esta razón, esperar una “señal” no es suficiente. Para cuando sientes algo, el daño ya podría estar hecho. Los exámenes de detección regulares son vitales porque no siempre puedes confiar en cómo se siente tu cuerpo.

Conclusión 3: Tienes mucho más colesterol del que realmente necesitas

Oímos mucho sobre colesterol, pero la mayoría de nosotros no sabe de dónde proviene ni cuánto necesitamos realmente. Piense en su cuerpo como un “constructor experto”. Sus células son increíblemente inteligentes; pueden fabricar sus propios suministros para mantenerse fuertes. Esto incluye producir todo el colesterol que su cuerpo necesita para construir paredes celulares y hormonas.

El estadounidense promedio tiene alrededor de 5.6 gramos de colesterol circulando por la sangre en un momento dado. Eso es más o menos el peso de una sola moneda de cinco centavos de EE. UU. Parece una cantidad pequeña, pero en realidad su cuerpo solo necesita entre 1.5 y 2.7 gramos para mantenerse saludable.

Esto significa que la mayoría de nosotros llevamos el doble de colesterol del que necesitamos. ¿De dónde viene el extra? Proviene de la “dieta estándar estadounidense”, llena de productos de origen animal proteínas, productos lácteos y aceites añadidos. Este colesterol extra es como “basura” flotando en tus tuberías. Cuando hay demasiada basura, empieza a atascarse en las paredes de tus arterias. Tu cuerpo ya es experto en fabricar sus propios suministros; las cosas extra en tu sangre solo están esperando para causar un embotellamiento.

Conclusión 4: La reversión “imposible” (Las arterias pueden volver a abrirse)

Durante mucho tiempo, muchos médicos creyeron que una vez que un arteria estaba totalmente bloqueada, se quedaba bloqueada para siempre a menos que un cirujano usara un balón o un tubo de metal (llamado stent) para solucionarlo. El caso de Peter demostró que el corazón tiene una capacidad asombrosa para ayudarse a sí mismo si el entorno se mantiene perfectamente limpio.

En 2014, los exámenes médicos de Peter revelaron que una de sus arterias coronarias principales estaba casi totalmente obstruida (lo que significa que estaba bloqueada en un 70%).. Ninguna sangre podía pasar por esa tubería en absoluto. Pero Peter no se rindió simplemente. Inició un programa intensivo para “limpiar las tuberías”. Cambió su dieta a una basada en alimentos integrales de origen vegetal (PBPB) plan sin aceite. Siguió haciendo ejercicio y usó medicamentos específicos, incluidos Niacina y “inhibidores de PCSK9” (un medicamento especial que ayuda al hígado a eliminar la basura de la sangre). Logró reducir sus niveles de colesterol “malo” hasta un “nadir” (el punto más bajo) de apenas 21 mg/dL.

Cuatro años después, en 2018, Peter se sometió a otro examen. Los resultados fueron “inusuales y significativos”. La arteria que antes estaba 70% obstruida ahora estaba “patente”—lo que significaba que estaba abierto y fluyendo nuevamente.

“El estudio de 2018 demostró... la primera rama diagonal, previamente ocluida por completo, apareció permeable con flujo de contraste anterógrado hacia el vaso distal.”

Esto se llama “recanalización”(lo cual es una forma elegante de decir que una tubería obstruida vuelve a abrirse). Es como una carretera bloqueada que se despeja para que el tráfico pueda fluir de nuevo. Al reducir sus niveles de colesterol “malo” a niveles extremadamente bajos y comer únicamente alimentos de origen vegetal, Peter ayudó a su cuerpo a hacer lo “imposible”. Sus arterias no solo dejaron de empeorar, sino que realmente volvieron a abrirse.

Conclusión 5: Por qué una calificación de “estrella dorada” podría estar mintiéndote

Muchas personas van al médico y obtienen un resultado de colesterol “normal”. Ven un número como 80 o 100 para su LDL (el colesterol “malo”) y creen que están a salvo. Pero una prueba estándar puede ser como “esconder la suciedad debajo de una alfombra”. El piso se ve limpio porque no se puede ver la suciedad, pero el desorden sigue estando allí debajo.

Hay una forma mucho mejor de medir tu riesgo, y se llama “ApoB.” Para entender esto, imagine que el colesterol en su sangre es “basura” y hay “camiones de basura” transportándolo. Una prueba de LDL estándar solo mide el peso de la basura. Pero el verdadero peligro es el número de camiones En el camino.

La ApoB mide la cantidad de camiones. Incluso si no tienes mucha basura, tener demasiados camiones (una puntuación alta de ApoB) puede causar un embotellamiento masivo y acumulación en tus arterias. Si solo miras el peso (LDL), podrías pasar por alto el hecho de que los “camiones” siguen causando daños. El éxito de Peter provino de mirar más allá de las puntuaciones básicas y utilizar la prueba de ApoB para asegurarse de que su sangre estuviera lo más limpia posible.

El plan para un “corazón más fuerte”

Revertir las enfermedades cardíacas no es magia. Se necesita un plan específico que combine ciencia, comida y movimiento. Peter usó un método que transformó su cuerpo de un “auto deportivo obstruido” nuevamente a un ganador de récord mundial.

El Reversión Rutina

Tarea pendiente	Por qué funciona
Dieta basada en plantas de alimentos enteros	Se enfoca en las plantas y evita todos los aceites para mantener la sangre “limpia”. Esto evita que se forme nueva suciedad y permite que el cuerpo comience el proceso de limpieza.
Manejo lipídico agresivo	El uso de medicamentos para llevar el colesterol “malo” (LDL y ApoB) a niveles de “nadir” (como los 21 mg/dL de Peter). Esto es lo suficientemente bajo como para activar al cuerpo para que reduzca la placa.
Ejercicio estructurado (de 6 a 10 horas a la semana)	Fortalece el corazón y ayuda al cuerpo a desarrollar vasos sanguíneos de “respaldo”. El de Peter“VO2 máx”(qué tan bien su cuerpo utiliza el oxígeno) ¡saltó de 56 a 65!
Monitoreo del rendimiento	No esperes simplemente a que aparezca el dolor. Rastrea la potencia de tu “motor” (como la velocidad al pedalear o el ritmo al caminar) para detectar problemas antes de que se conviertan en ataques cardíacos “fantasma”.

Conclusión: ¿Es la enfermedad cardíaca una elección?

Las enfermedades cardíacas son la principal causa de muerte entre hombres y mujeres, pero la historia de Peter Megdal nos demuestra que no tienen por qué ser una sentencia de muerte. Pasó de tener una arteria obstruida 70% a volver a batir récords mundiales en 2025. No esperó a que un infarto “fantasma” le cambiara la vida. Notó que su energía disminuía y tomó medidas de inmediato.

Entonces, ¿la enfermedad cardíaca es una elección? Si bien no podemos controlar nuestros historial familiar, podemos controlar el entorno dentro de nuestras “tuberías”. Piénselo como una carretera que ha estado cerrada durante años. La mayoría de la gente piensa que esa carretera ha desaparecido para siempre. Pero con el “equipo de limpieza” adecuado de alimentos de origen vegetal y el medicamento correcto para retirar los “camiones de basura”, esa carretera puede abrirse una vez más.

¿Estás listo para mirar tu propio “medidor de potencia” y ver lo que tu corazón está tratando de decirte? No te conformes con una “estrella dorada” en una prueba básica que podría estar ocultando la verdad. Empodérate pidiéndole a tu médico una prueba de ApoB. La elección de construir un corazón más fuerte y una vía clara para tu salud comienza hoy.

Inmersión profunda

Regresión de la aterosclerosis, estabilización de placas y armonización de imágenes intermodales

Una exhaustiva Revisión narrativa de estrategias mecanicistas, farmacológicas y de estilo de vida para la enfermedad Reversión

Resumen

Antecedentes. Aterosclerótico enfermedad cardiovascular (ASCVD) sigue siendo la mayor causa individual de mortalidad en todo el mundo. Durante las últimas dos décadas, el manejo clínico de enfermedad de las arterias coronarias ha experimentado un cambio conceptual fundamental, pasando de la reducción pasiva de lípidos hacia la inducción activa de regresión de la placa, cápsula fibrosa espesamiento, y núcleo necrótico depleción. Ensayos clínicos seriados de imágenes intravasculares y no invasivas, ensayos aleatorizados de resultados cardiovasculares e investigaciones mecanísticas de apolipoproteína B (apoB)-que contiene lipoproteína la retención han transformado colectivamente ateroesclerosis de una enfermedad progresiva a una que se puede revertir de manera medible.

Objetivo. Para sintetizar la evidencia mecanística, basada en imágenes, sobre el estilo de vida y farmacológica que respalda una estrategia terapéutica unificada y de múltiples vías para la regresión de la aterosclerosis y la prevención de eventos cardiovasculares adversos mayores (MACE), con atención explícita al rigor de las citas, la armonización de imágenes multimodales y la reconciliación de la aparente paradoja entre la volumetría modesta placa regresión y grandes reducciones en los eventos clínicos.

Métodos. Se realizó una revisión narrativa estructurada en PubMed/MEDLINE, EMBASE y la Cochrane Library hasta abril de 2026. Las búsquedas priorizaron publicaciones primarias en The Lancet, New England Journal of Medicine, JAMA, Circulation, Journal of the American College of Cardiology, European Heart Journal, Atherosclerosis, Journal of Clinical Investigation, y Arterioesclerosis, Trombosis, y Biología Vascular. Se recuperaron por nombre los principales ensayos de resultados cardiovasculares, estudios de imágenes en serie e investigaciones mecanísticas. Los hallazgos se contrastaron con Cochrane revisiones sistemáticas y las más recientes de la Sociedad Europea de Cardiología (ESC) y las conjuntas de la Asociación Americana del Corazón y el Colegio Americano de Cardiología (AHA/ACC) colesterol, prevención y revascularización pautas.

Principales hallazgos. La partícula de apoB hipótesis de retención [28,29,30sigue siendo la base mecanística unificadora para aterogénesis. Los metaanálisis de la Colaboración Cholesterol Treatment Trialists’ (CTT) [1,2] estableció un relación log-lineal entre la reducción absoluta del colesterol LDL y la tasa de eventos vasculares graves, con un 22% riesgo relativo reducción por cada disminución de 1 mmol/L (≈39 mg/dL) (razón de tasas: 0,78; IC 95 %: 0,76–0,80). Fourier [3] demostró una reducción de 15% en el criterio de evaluación cardiovascular primario compuesto con evolocumab (HR 0,85; IC 95 % 0,79–0,92; p < 0,001) en un contexto de estatinas terapia. Odisea RESULTADOS [4] demostró una reducción del 15% en los eventos cardiovasculares mayores (MACE) con alirocumab en pacientes con síndrome coronario agudo (SCA) (HR 0,85; IC 95 % 0,78–0,93; p < 0,001) y una reducción nominalmente significativa en mortalidad por todas las causas (HR 0,85; IC 95 % 0,73–0,98; p = 0,026). Júpiter [5] estableció que rosuvastatina 20 mg al día en pacientes de prevención primaria con alta sensibilidad elevada Proteína C reactiva (hsCRP ≥2 mg/L) redujo el punto de terminación compuesto por 44% (HR 0,56; IC 95% 0,46–0,69; p < 0,00001).

De serie ecografía intravascular ensayos—REVOCACIÓN [7], ASTEROIDE [8], Saturno [9], GLAGOV [10], PACMAN-AMI [11]—y coronaria tomografía computarizada ensayos de angiografía (CCTA), incluido EVAPORATE [22] y el registro PARADIGM [44] demostró de manera consistente que los niveles de colesterol LDL (LDL-C) inferiores a 70 mg/dL detienen la progresión de la placa, mientras que los niveles inferiores a 30–40 mg/dL provocan una regresión medible en el 60–80% de los sujetos tratados. La acción antiinflamatoria dirigida a través de canakinumab en CANTOS [15] (HR de 0,85 para la dosis de 150 mg, IC 95 %: 0,74–0,98, p = 0,021) y a través de colchicina en COLCOT [13] (HR 0,77; IC 95 % 0,61–0,96; p = 0,02), LoDoCo2 [14] (HR 0,69, IC 95 % 0,57–0,83, p < 0,001), y COLOCT [12] (engrosamiento significativo de la capa fibrosa y reducción del arco lipídico) redujo sustancialmente los eventos cardiovasculares independientemente de hipolipemiante. Ácido bempedoico en Resultados CLEAR [16] (HR 0,87; IC 95 % 0,79–0,96; p = 0,004) amplió la reducción de eventos a las poblaciones con intolerancia a las estatinas. Las nuevas terapias dirigidas al ARN—inclisirán [17] y los agentes dirigidos a la lipoproteína(a) pelar carne [18] y olpasiran [19]—lograr reducciones sostenidas y profundas de las lipoproteínas aterogénicas con una dosificación trimestral o semestral.

Intervenciones intensivas sobre el estilo de vida: patrones dietéticos basados en plantasEnsayo sobre el estilo de vida y el corazón [20,21], intervención estilo DASH en DISCO-CT [35]), y supervisado ejercicio aeróbico (Madssen et al. [27])—producir estructural y duradero biomarcador mejoras concordantes con la regresión definida por imágenes. Un protocolo de combinación de múltiples vías que logra simultáneamente un C-LDL ultrabajo, inhibe inflamasoma NLRP3 la activación, agota la lipoproteína residual y el riesgo inflamatorio, y refuerza la biología vascular a través de la conversión de dieta y ejercicio placas vulnerables en cicatrices quiescentes, microcalcificadas y fibrosas que resisten la ruptura.

Conclusiones. La regresión de la placa coronaria y la prevención de eventos clínicos ya no son objetivos ambiciosos; son alcanzables mediante la aplicación deliberada y basada en la evidencia de la terapia pleiotrópica. La paradoja volumen-resultado —en la que reducciones modestas de 1–3% en volumen de placa que da lugar a reducciones de 15–30% en los eventos clínicos graves —se explica desde el punto de vista mecánico por la estructura estabilización de la placaengrosamiento de la cubierta fibrosa, depleción del núcleo necrótico, macrófago autorización y conversión de irregular a denso calcificación. Las futuras investigaciones deben perfeccionar los algoritmos de escalamiento personalizado, validar los biomarcadores de imagen no invasivos, establecer la seguridad a largo plazo del logro de C-LDL ultra bajo combinado con terapia antiinflamatoria y traducir las terapias dirigidas a la Lp(a) a una práctica validada por resultados.

Palabras clave

regresión de la aterosclerosis; colesterol LDL; apolipoproteína B; inhibidores de la PCSK9; canakinumab; colchicina; angiografía por tomografía computarizada coronaria; ultrasonido intravascular; tomografía de coherencia óptica; prevención cardiovascular; lipoproteína(a); riesgo inflamatorio residual; dieta basada en plantas; entrenamiento en intervalos de alta intensidad

Abreviaturas

ACS — síndrome coronario agudo

AHA/ACC — Asociación Estadounidense del Corazón / Colegio Estadounidense de Cardiología

AI-QCT — tomografía computarizada cuantitativa por inteligencia artificial

apoA-I / apoB — apolipoproteína A-I / apolipoproteína B

ECV — enfermedad cardiovascular aterosclerótica

CAC — coronario arteria calcio

CCTA angiografía por tomografía computarizada coronaria

CTT — Colaboración de los Ensayos de Tratamiento del Colesterol

EEM — membrana elástica externa

eNOS — endotelial óxido nítrico sintasa

EPA — ácido eicosapentaenoico

ESC — Sociedad Europea de Cardiología

FCT — espesor de la capa fibrosa

ARGLP-1 agonista del receptor del péptido-1 similar al glucagón

c-HDL — colesterol de lipoproteínas de alta densidad

HIIT / MCT — entrenamiento interválico de alta intensidad / entrenamiento continuo moderado

PCRat — proteína C reactiva de alta sensibilidad proteína

ICA — angiografía coronaria invasiva

IL-1β / IL-6 — interleucina-1 beta / interleucina-6

IPE — etil de icosapento

IVUS / VH-IVUS — ecografía intravascular / IVUS por histología virtual

LAP / LAPV — placa de baja atenuación volumen de placa de baja atenuación

LDL-C — colesterol de lipoproteínas de baja densidad

Lp(a) — lipoproteína(a)

LXR — receptor X hepático

MACE — eventos cardiovasculares adversos mayores

MI — infarto de miocardio

MMP — metaloproteinasa de la matriz

NLRP3 — Familia NLR, dominio pirina que contiene 3 (inflamasoma)

NNT — número necesario a tratar

OCT — tomografía de coherencia óptica

oxLDL — lipoproteína de baja densidad oxidada

PAV — volumen percentual de ateroma

PCSK9 — proproteína convertasa subtilisina/kexina tipo 9

ROS — especies reactivas del oxígeno

SGLT2 cotransportador de sodio-glucosa tipo 2

TAV — total ateroma volumen

TCFA — fibroateroma de capa fina

TNCP — total placa no calcificada

VCAM-1 / ICAM-1 — molécula de adhesión celular vascular / intercelular-1

PBPB — basado en plantas de alimentos enteros

1. Introducción

La enfermedad cardiovascular aterosclerótica (ECVA) representa aproximadamente un tercio de la mortalidad mundial y sigue siendo la principal causa de muerte en las economías industrializadas. Durante más de medio siglo, el manejo clínico siguió un paradigma progresivo: identificar el riesgo, retrasar la progresión e intervenir mecánicamente cuando isquemia se volvió sintomático. Este paradigma generó un beneficio considerable —la mortalidad coronaria ajustada por edad se redujo en aproximadamente 50% en los Estados Unidos entre 1980 y 2010—, pero aceptaba como inevitable la historia natural de la aterosclerosis como una acumulación inexorable de lípidos y carga inflamatoria en las arterias, modulada solo marginalmente por la farmacoterapia y la revascularización.

La acumulación de evidencia de las últimas dos décadas ha desmantelado ese fatalismo. Las observaciones seminales de Glagov y sus colegas [34] estableció que hacia afuera compensatorio remodelación arterial máscaras sustanciales carga de placa hasta etapas avanzadas de la progresión de la enfermedad, un hallazgo que explicó simultáneamente el fracaso de la angiografía luminal para predecir eventos agudos y motivó el desarrollo de modalidades de imagen intravascular que visualizan la pared arterial misma. Los ensayos clínicos seriados de ultrasonido intravascular (IVUS) de principios de la década de 2000 —REVERSAL [7], ASTEROIDE [8], SATURN [9]—demostró por primera vez que la reducción intensiva de lípidos con estatinas no solo detuvo, sino que, en poblaciones seleccionadas, revirtió la carga de placa coronaria. La era de los inhibidores de PCSK9, inaugurada por FOURIER [3] y ODYSSEY OUTCOMES [4] y extendido a la imagen por GLAGOV [10] y PACMAN-AMI [11], redujeron los niveles alcanzables de c-LDL por debajo de 30 mg/dL y confirmaron que la regresión era reproducible de manera confiable a escala poblacional.

Los descubrimientos paralelos reformularon el marco inflamatorio de la aterogénesis. Los estudios de secuenciación de ARN monocelular de Cochain [31], Williams [32], y otros revelaron que los macrófagos íntimales no existen como una dicotomía binaria M1/M2, sino como un continuo de estados de activación, incluidos el fenotipo M4 inducido por la quimiocina derivada de plaquetas CXCL4, el fenotipo Mox inducido por fosfolípidos oxidados, el fenotipo Mhem resolvedor de hemorragias y el subconjunto Trem2⁺ cargado de lípidos enriquecido en la regresión lesiones [33]. CANTOS [15] luego proporcionó la prueba clínica definitiva de que la terapia antiinflamatoria, dirigida a la interleucina-1β con canakinumab, reduce los eventos cardiovasculares independientemente de cualquier efecto sobre el C-LDL, lo que valida el concepto de riesgo inflamatorio residual [42,43] y abriendo un eje terapéutico paralelo.

Avances simultáneos en imágenes, en particular la angiografía por tomografía computarizada coronaria (CCTA) con análisis cuantitativo impulsado por inteligencia artificial (AI-QCT) [44,45], espectroscopia de infrarrojo cercano (NIRS), y tomografía de coherencia óptica (OCT) de alta resolución [48]—ahora permiten el seguimiento longitudinal no invasivo de la composición de la placa con resolución submilimétrica. Combinadas con rigurosos protocolos de armonización intermodal en laboratorios centrales, estas tecnologías permiten la medición seriada del grosor de la capa fibrosa, núcleo lipídico volumen, infiltración de macrófagos y los índices de remodelado, transformando la biología de la placa de inferida a observada.

Por último, la investigación sobre el estilo de vida —desde el fundamental Lifestyle Heart Trial [20,21] a través de la intervención dietética DISCO-CT más reciente [35] y los ensayos de IVUS guiado por ejercicio de Madssen y colaboradores [27]—ha demostrado que la dieta y la actividad física ejercen efectos biológicamente significativos y estructuralmente medibles en la pared arterial coronaria, produciendo cambios biomarcadores y morfológicos que son paralelos a la regresión farmacológica.

A pesar de estos avances, la práctica clínica contemporánea sigue subtratando la aterosclerosis. Los registros del mundo real muestran que una minoría de pacientes con enfermedad coronaria establecida alcanza las metas de c-LDL recomendadas por las guías, y que la terapia antiinflamatoria, el abordaje del riesgo residual y la intervención estructurada sobre el estilo de vida siguen implementándose de manera inconstante. Por lo tanto, la oportunidad clínica no radica en el descubrimiento de nuevos fármacos, sino en la integración racional de las terapias existentes y validadas en un protocolo unificado de múltiples vías fundamentado en el mecanismo, la imagen médica y los resultados clínicos.

Esta revisión narrativa sintetiza la evidencia mecanicista, basada en imágenes, sobre el estilo de vida y farmacológica que respalda la regresión de la aterosclerosis y la estabilización de la placa. Está organizada para seguir la lógica biológica de la enfermedad: desde la iniciación molecular de la aterogénesis (Sección 3) hasta las modalidades de imagen que la visualizan (Sección 4), las intervenciones en el estilo de vida que la modulan (Sección 5), la farmacoterapia que impulsa la regresión (Sección 6) y la síntesis de múltiples vías que integra estas palancas en una estrategia clínica coherente (Sección 7). La discusión (Sección 8) aborda la paradoja de volumen-resultado, el riesgo inflamatorio residual, las barreras de implementación clínica y las preguntas metodológicas sin resolver. La conclusión (Sección 9) articula la afirmación central que se desprende de esta evidencia: que la aterosclerosis es ahora una enfermedad reversible y que la principal barrera para su reversión generalizada ya no es biológica, sino operativa.

2. Métodos

Esta revisión narrativa se llevó a cabo entre enero y abril de 2026 con el objetivo explícito de sintetizar la evidencia primaria de la más alta calidad sobre regresión de la aterosclerosis coronaria, estabilización de placas y armonización de imágenes intermodales. La metodología, aunque no se adhiere a los estándares de revisión sistemática PRISMA, se estructuró para maximizar el rigor en las citas, minimizar la dependencia de fuentes terciarias y garantizar la trazabilidad transparente de cada afirmación numérica hasta su publicación primaria.

2.1 Estrategia de búsqueda

Se realizaron búsquedas en PubMed/MEDLINE, EMBASE, el Registro Central de Ensayos Controlados de Cochrane (CENTRAL) y la Base de Datos Cochrane de Revision Sistemáticas. Las búsquedas combinaron vocabulario controlado (MeSH/Emtree) y términos de texto libre en los siguientes dominios: (a) metabolismo lipídico y lipoproteínas que contienen apoB; (b) aterogénesis, biología de la placa y vascular inflamación; (c) intravascular y no invasivo imágenes coronarias (IVUS, VH-IVUS, OCT, CCTA, NIRS, CAC, IA-QCT); (d) ensayos de resultados cardiovasculares de estatinas, inhibidores de la PCSK9, ezetimiba, ácido bempedoico, inclisirán, etil eicosapentaenoico, colchicina, canakinumab, inhibidores de SGLT2, agonistas del receptor de GLP-1, y terapias dirigidas a la Lp(a); (e) intervenciones en el estilo de vida, incluidas dietas basadas en plantas muy bajas en grasas, patrones dietéticos mediterráneo y DASH, y protocolos de ejercicio aeróbico.

Los ensayos pivotales —FOURIER, ODYSSEY OUTCOMES, JUPITER, REVERSAL, ASTEROID, SATURN, GLAGOV, PACMAN-AMI, REDUCE-IT, EVAPORATE, CHERRY, CANTOS, COLCOT, LoDoCo2, COLOCT, CLEAR Outcomes, ORION-10/11, el Lifestyle Heart Trial, DISCO-CT, LEADER, SUSTAIN-6, EMPA-REG OUTCOME y los metaanálisis de los Cholesterol Treatment Trialists— se recuperaron por su nombre para garantizar que no se pasara por alto ningún estudio histórico debido a variaciones en la indización.

2.2 Jerarquía de calidad de las fuentes

La prioridad de citación se asignó en el siguiente orden descendente:

Publicaciones principales en revistas principales de cardiología y medicina general de alto nivel: The Lancet, New England Journal of Medicine, JAMA, JAMA Cardiology, Circulation, Circulation Research, Journal of the American College of Cardiology, JACC: Cardiovascular Imaging, European Heart Journal, Atherosclerosis, Journal of Clinical Investigation, y Arteriosclerosis, Thrombosis, and Vascular Biology.
Revisiones sistemáticas y metaanálisis de Cochrane indexados en la Base de Datos de Revisiones Sistemáticas Cochrane.
Documentos de guías y declaraciones científicas actuales de la Sociedad Europea de Cardiología, la conjunta de la AHA/ACC y la conjunta de la AHA/ACC/Multisociedad.
Documentos de consenso de la Sociedad Europea de Aterosclerosis, la Sociedad Internacional de Aterosclerosis y documentos de normas de la Sociedad de Tomografía Computarizada Cardiovascular.
Publicaciones primarias mecanicistas en Nature, Nature Medicine, Nature Reviews Cardiology, Cell, Cell Metabolism, y Inmunidad para las bases moleculares y celulares.

Las recuperaciones de solo resumen (publicaciones de las cuales solo se pudo acceder al resumen durante el periodo de revisión) se retuvieron y marcaron como [Resumen Verificado] en la lista de referencias en lugar de excluirse, con el fin de preservar la cobertura de la literatura emblemática tras muro de pago. Las fuentes no primarias (preprints sin revisión por pares posterior, blogs de sociedades, medios de noticias legos y comentarios terciarios) se excluyeron, excepto cuando se utilizaron para corroborar declaraciones de consenso que también fueron citadas de manera independiente a partir de fuentes primarias.

2.3 Verificación numérica

Cada cociente de riesgos instantáneos, 95% intervalo de confianza, valor p, el número necesario a tratar, el tamaño del efecto, el cambio porcentual y el valor de concentración informados en el texto se rastrearon hasta su publicación primaria. Cuando un valor apareció tanto en la publicación del ensayo principal como en una guía posterior o metaanálisis, se citó la publicación principal. Cuando se disponía de valores preliminares junto con los valores finales publicados, se utilizó el valor final publicado. Tres valores —la fracción de pacientes que no respondieron al espesor de la capa fibrosa de Yellow III (aproximadamente 30%), la reducción del arco lipídico en grados según COLOCT (Δ ≈ –31°) y la tasa anual de progresión de la placa no calcificada según PARADIGM— se han marcado en el texto como de confianza media, a la espera de una verificación cruzada definitiva con los archivos PDF de las fuentes primarias, y podrían requerir una verificación editorial antes de su envío para publicación.

Verificación cruzada de directrices

Las afirmaciones clínicas clave se contrastaron con las Guías de la ESC/EAS de 2019 para el manejo de las dislipidemias, las Guías de la ESC de 2021 sobre la prevención de enfermedades cardiovasculares, la guía de la AHA/ACC/Multisociedad de 2018 sobre el manejo del colesterol en sangre, la guía de la AHA/ACC/Multisociedad de 2023 para el manejo de pacientes con enfermedad coronaria crónica, y las revisiones sistemáticas de Cochrane relevantes sobre estatinas, inhibidores de PCSK9 y terapia hipolipemiante. Cuando las guías diferían en los valores de umbral (por ejemplo, las metas de c-LDL en pacientes de muy alto riesgo prevención secundaria), ambas posiciones se informan con sus documentos de origen.

2.5 Alcance y limitaciones del enfoque de la revisión

Esta es una revisión narrativa, no sistemática, y por lo tanto está sujeta a las limitaciones inherentes de la síntesis selectiva: no se realizó una evaluación formal del riesgo de sesgo para los ensayos individuales; no se llevó a cabo un metaanálisis cuantitativo; y la inclusión de evidencia reflejó el criterio académico de relevancia en lugar de criterios de inclusión predefinidos. El compromiso aceptado en favor de la síntesis narrativa es la profundidad de la integración mecanicista y clínica a través de líneas de evidencia heterogéneas (biología celular, física de imágenes, ensayos de resultados, ciencia del estilo de vida) que una revisión sistemática de alcance limitado no abarcaría. Los lectores deben considerar las recomendaciones de la Sección 7 como orientación clínica sintetizada por expertos, fundamentada en la evidencia primaria citada, y no como el resultado de un proceso sistemático registrado.

3. Fundamentos mecanicistas de la aterogénesis y la regresión

3.1 La hipótesis de la retención de partículas de apoB

El fundamento mecanístico unificador de la aterosclerosis es la hipótesis de respuesta a la retención, articulado por Williams y Tabas en 1995 [29], ampliado por Tabas, Williams y Borén en 2007 [28], y codificado más recientemente en la declaración de consenso de la Sociedad Europea de Aterosclerosis de 2020 [30]. The hypothesis holds that atherogenesis is initiated when apolipoprotein B (apoB)-containing lipoproteins—principally low-density lipoprotein (LDL), but also remnant lipoproteins, intermediate-density lipoprotein (IDL), and lipoprotein(a) [Lp(a)]—cross the endothelial barrier and are retained within the subendothelial íntima through ionic interactions between apoB and intimal matriz extracelular proteoglicanos, en particular biglucán and decorin. Once retained, these lipoproteins undergo oxidative and enzymatic modifications that render them immunogenic, triggering the cascade of endothelial activation, monocyte recruitment, macrophage foam-cell formation, and chronic inflammation that defines plaque biology.

The retention model has three clinically decisive implications. First, atherogenesis is dose-dependent on the concentration of circulating apoB particles—not on cholesterol mass per se, but on the number of partículas aterogénicas available to traverse and become retained within the arterial intima. Second, the relationship between apoB particle concentration and plaque burden is approximately log-linear, mirroring the log-linear relationship between achieved LDL-C and cardiovascular event rate established by the Cholesterol Treatment Trialists’ meta-analyses [1,2]. Third, atherogenesis is reversible: when apoB particle entry is reduced below the rate of particle clearance and intimal lipid efflux, the equilibrium of the arterial wall shifts toward net regression. This third implication is the biological foundation for every pharmacologic regression strategy discussed in Section 6.

The retention model also explains why apoB measurement, where available, is superior to LDL-C for risk stratification: LDL-C measures cholesterol mass, while apoB measures particle number, and in discordant cases—particularly in patients with síndrome metabólico, hypertriglyceridemia, or small-dense LDL phenotypes—apoB more accurately reflects atherogenic burden [30]. Contemporary guidelines, particularly the 2019 ESC/EAS dyslipidaemia guidelines, accordingly recognize apoB as an acceptable, and in selected patients preferred, target of lipid-lowering therapy.

3.2 Endothelial activation and monocyte recruitment

Retention of modified apoB lipoproteins triggers the overlying células endoteliales to express vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1), facilitating the rolling, adhesion, and transendothelial migration of circulating Ly6Cʰⁱ classical monocytes [33]. Once within the intima, recruited monocytes encounter macrophage colony-stimulating factor (M-CSF) and differentiate into macrophages. These macrophages, expressing scavenger receptors (CD36, SR-A) and lectin-like LDL oxidada receptor 1 (LOX-1), avidly engulf retained, oxidized, and aggregated LDL particles, transforming into lipid-laden células espumosas—the histologic signature of early atheroma.

Endothelial activation is also amplified by shear-stress patterns: regions of low or oscillatory esfuerzo cortante en la pared, particularly at arterial branch points and inner curvatures, are predisposed to lipoprotein retention and activation, explaining the well-established anatomic distribution of plaques at coronary bifurcations and the proximal segments of the left anterior descending and circumflex arteries. Conversely, high-laminar shear stress upregulates óxido nítrico sintasa endotelial (eNOS) and Krüppel-like factor 2 (KLF2), producing an atheroprotective endothelial transcriptional program—a mechanism that explains, in part, the vascular benefit of structured aerobic exercise (Section 5.3).

3.3 Macrophage heterogeneity in plaque progression and regression

The cellular landscape of human atheroma has been refined dramatically by single-cell RNA sequencing. The simplified M1/M2 binary—classically activated, pro-inflammatory macrophages versus alternatively activated, tissue-healing macrophages—has been replaced by a richer taxonomy of activation states defined by transcriptional signatures, metabolic substrate use, and topographic distribution within the plaque [31,32,33].

M1 macrophages, fueled predominantly by anaerobic glycolysis under transcriptional control of nuclear factor-κB (NF-κB) and signal transducer and activator of transcription 1 (STAT1), localize to the unstable, placa rica en lípidos core. They secrete interleukin-1β (IL-1β), interleucina-6 (IL-6), tumor necrosis factor-α (TNF-α), and reactive oxygen species (ROS), driving fibrous cap thinning and matrix metalloproteinase (MMP)-mediated cap degradation.

M2 macrophages, fueled by mitochondrial fatty acid oxidation and regulated by signal transducer and activator of transcription 6 (STAT6), interferon regulatory factor 4 (IRF4), Krüppel-like factor 4 (KLF4), and peroxisome proliferator-activated receptor-γ (PPARγ), are enriched in regressing plaques. They express CD163, mannose receptor 1 (CD206), and arginase-1, secrete transforming growth factor-β (TGF-β) and collagen, and contribute to plaque stabilization and resolution of inflammation.

M4 macrophages, induced by the platelet-derived chemokine CXCL4 (platelet factor 4), are characterized by complete downregulation of the hemoglobin-haptoglobin scavenger receptor CD163. This deficit prevents the upregulation of the cytoprotective enzyme heme oxygenase-1 (HO-1) in response to hemorragia intraplaca. M4 macrophages also exhibit defective phagocytic and efferocytotic capacity, while producing MMP-7, S100A8, IL-6, and TNF-α, directly accelerating fibrous cap degradation and necrotic core expansion.

Mox macrophages, induced by oxidized phospholipids in oxidized LDL, protect against estrés oxidativo through nuclear factor erythroid 2-related factor 2 (NRF2)-driven expression of heme oxygenase-1, thioredoxin reductase 1, and sulfiredoxin-1.

Mhem macrophages, enriched at sites of intraplaque hemorrhage, are atheroprotective: they phagocytose erythrocyte remnants, clear free hemoglobin, and resist foam-cell formation through high expression of liver X receptors (LXRα and LXRβ) and the ATP-binding cassette cholesterol efflux transporters ABCA1 and ABCG1.

Trem2⁺Cd9⁺Spp1⁺ macrophages, identified in murine and human single-cell atlases [31,32], represent a specialized lipid-handling population: lipid-rich, with high expression of cathepsin D and osteopontin, but low expression of pro-inflammatory cytokines. These cells appear to play a homeostatic role in lipid management within established plaques and are enriched in lesions undergoing regression.

The clinical importance of this taxonomy is that regression is not merely the absence of progression: it is an active biological process characterized by phenotypic switching of resident plaque macrophages from M1/M4 toward M2/Mhem/Trem2⁺ states, with concurrent egress of inflammatory monocytes from the lesion and ingress of resolving cell populations [33]. Pharmacologic and lifestyle interventions that achieve regression at the imaging level can be understood as those that drive this phenotypic switch.

3.4 Translational validity of preclinical models

Mechanistic insights have been derived primarily from genetically modified mouse models—apoE⁻/⁻ and LDLR⁻/⁻ mice fed atherogenic diets—and from rabbit and porcine models. In apoE⁻/⁻ mice, sustained hipercolesterolemia drives a heavily M1-skewed inflammatory infiltrate. When hypercholesterolemia is reversed—via aortic transplantation into normolipidemic recipients, hepatic gene therapy with apoE reconstitution, or microsomal triglyceride transfer protein (MTP) inhibition—monocyte recruitment ceases within days, and resident plaque macrophages undergo phenotypic polarization from M1 toward M2 in a manner dependent on STAT6 signaling [33].

Translational validity of the CXCL4/M4 axis is supported by the genetic knockout of Pf4 (encoding CXCL4) in apoE⁻/⁻ mice, which produces significant reductions in total atheroma burden, decreased macrophage accumulation, reduced vascular cell adhesion molecule expression, and accelerated dissolution of cholesterol clefts within the arterial wall—recapitulating the cellular hallmarks of human stable, regressing plaque.

Important caveats apply. Murine atherosclerosis differs from human disease in temporal scale (months vs. decades), lipoprotein profile (apoB-48 vs. apoB-100 dominance), and plaque morphology (limited spontaneous cap rupture). Pharmacologic findings in mice therefore require human validation through serial imaging trials before clinical inference. The serial-IVUS and OCT trials reviewed in Section 6 serve precisely this validation function.

3.5 Human biomarkers of plaque vulnerability

While systemic biomarkers—LDL-C, apoB, non-HDL-C, Lp(a), and hsCRP—remain clinical standards for ASCVD risk estimation, they do not directly reflect the active cellular landscape of the arterial wall. Platelet-derived chemokines, specifically CXCL4 and RANTES (CCL5), serve as more proximal markers of intravascular thromboinflammation. CXCL4 promotes macrophage foam-cell formation by enhancing the cellular uptake of oxidized lipoproteins; RANTES drives leukocyte recruitment to the activated endotelio.

The clinical relevance of CXCL4 as a tractable, modifiable biomarker is demonstrated by the DISCO-CT randomized trial [35], in which dietitian-led intensive DASH-style dietary intervention produced sustained suppression of circulating CXCL4 in patients with non-obstructive coronary disease. Notably, CXCL4 suppression in DISCO-CT was durable even six years after cessation of active coaching, despite anthropometric and lipid rebound—suggesting that some elements of dietary vascular reprogramming persist beyond the active intervention period [35].

Additional emerging biomarkers include fosfolipasa A2 asociada a lipoproteínas (Lp-PLA2), growth differentiation factor 15 (GDF-15), and the inflammatory composite IL-6/hsCRP/fibrinogen, although none has yet been validated as a treatment target in randomized outcomes trials with the rigor applied to LDL-C, apoB, hsCRP (CANTOS), and triglicéridos (REDUCE-IT).

4. Multimodality Imaging of Plaque Burden, Composition, and Regression

Tracking plaque progression, regression, and morphologic stabilization requires a nuanced understanding of the strengths, limitations, and cross-modal alignment of intravascular and non-invasive imaging. The four modalities most relevant to contemporary regression science—coronary computed tomography angiography (CCTA), intravascular ultrasound (IVUS), optical coherence tomography (OCT), and traditional invasive coronary angiography (ICA)—differ in resolución espacial, tissue penetration, and the components of plaque biology they can resolve.

4.1 Coronary computed tomography angiography (CCTA)

CCTA is a non-invasive modality that produces volumetric, contrast-enhanced reconstructions of the entire coronary tree. Modern multi-detector and dual-source scanners achieve in-plane spatial resolution of approximately 0.3–0.5 mm and through-plane resolution of approximately 0.5–0.6 mm, with full coronary acquisition completed in a single breath-hold. CCTA identifies high-risk plaque features including low-attenuation plaque (LAP, defined by Hounsfield Unit thresholds of <30 HU and serving as a validated surrogate for the necrotic lipid core), spotty calcification, remodelación positiva, y el signo del anillo de servilleta [22,44].

CCTA’s principal strengths in regression science are its non-invasive nature, suitability for serial longitudinal imaging, and capacity to map the entire coronary tree rather than a single instrumented vessel. Its principal limitations are spatial resolution insufficient to directly resolve thin fibrous caps (the resolution gap to the histologically defined TCFA threshold of <65 µm is roughly an order of magnitude), calcification ‘blooming’ artifacts that can obscure the adjacent vessel lumen, and the small but non-zero exposición acumulativa to ionizing radiation and iodinated contrast media.

El Estudio EVAPORATE [22] used serial CCTA over 18 months to demonstrate that icosapent ethyl 4 g daily produced a 17% relative reduction in low-attenuation plaque volume compared with progression in placebo (between-group difference p<0.01), establishing CCTA as a credible non-invasive surrogate for plaque-composition change. The PARADIGM registry [44] applied CCTA to a large multicenter cohort and quantified the differential impact of statin therapy on plaque composition—statin-treated patients showed slower progression of total plaque burden but accelerated conversion of non-calcified to placa calcificada, consistent with imaging-defined stabilization.

4.2 Intravascular ultrasound (IVUS) and virtual histology IVUS

Intravascular ultrasound and its radiofrequency-derived variant, virtual histology IVUS (VH-IVUS), remain the gold standard for in vivo volumetric quantification of atheroma [47]. Using a 20–60 MHz catheter-based ultrasound transducer, IVUS measures the acoustic boundaries of the membrana elástica externa (MEE) and the luminal border, enabling precise calculation of percent atheroma volume (PAV) and volumen total de ateroma (VTA). Axial resolution is approximately 100–200 µm, with full-thickness vessel-wall imaging to the adventicia.

VH-IVUS analyzes the backscattered radiofrequency signal to classify plaque composition into four canonical components: fibrotic, fibrofatty, dense calcium, and necrotic core. Despite the high reproducibility of PAV/TAV measurements, IVUS resolution is insufficient to directly resolve thin fibrous caps; it can identify the presence of necrotic core and dense calcium but systematically misclassifies thin-cap fibroateroma (TCFA, cap thickness <65 µm) as thick-cap fibroatheroma. IVUS therefore quantifies plaque burden authoritatively but cannot adjudicate plaque vulnerability at the cap level.

Every major coronary regression trial of the past two decades—REVERSAL [7], ASTEROIDE [8], SATURN [9], GLAGOV [10], PACMAN-AMI [11]—has used IVUS seriado as its primary endpoint, anchored on PAV change between baseline and follow-up acquisitions of matched coronary segments.

4.3 Optical coherence tomography (OCT)

Optical coherence tomography uses near-infrared light backscattering at approximately 1300 nm wavelength to achieve axial resolution of 10–20 µm—approximately tenfold higher than IVUS [48]. This microscopic resolution makes OCT the only clinically deployed coronary imaging modality capable of directly measuring minimal fibrous cap thickness, identifying macrophage infiltration as bright punctate signals at the cap surface, and visualizing cristales de colesterol, neovascularización, and erosion sites.

The major constraints of OCT are shallow tissue penetration (1–3 mm, limited by light attenuation in lipid-rich tissue), the requirement for a transient contrast or saline flush during acquisition to clear blood from the imaging field, and the inability to visualize deep plaque boundaries or the external elastic membrane in highly attenuating lipid-rich plaques. These complementary strengths and weaknesses motivate cross-modal harmonization (Section 4.5).

OCT served as the primary imaging modality in the COLOCT trial [12], demonstrating that low-dose colchicine 0.5 mg daily, added to maximally tolerated lipid-lowering therapy in post-ACS patients with lipid-rich plaques, produced significant fibrous cap thickening, lipid arc reduction, and reduction in macrophage accumulation over 12 months. The Yellow III trial used serial OCT plus IVUS plus NIRS to triangulate the effects of evolocumab on plaque composition in statin-treated secondary-prevention patients.

4.4 Invasive coronary angiography (ICA)

Traditional invasive coronary angiography produces a high-resolution two-dimensional silhouette of the dye-filled vessel lumen, enabling determination of percent estenosis de diámetro y angiografía coronaria cuantitativa metrics. ICA remains the clinical standard for revascularization planning and was the modality used in the foundational Lifestyle Heart Trial [20,21], where it documented regresión angiográfica of percent diameter estenosis over one- and five-year follow-up.

ICA’s fundamental limitation is its geometric nature: it cannot visualize the arterial wall itself and is entirely blind to compensatory positive (outward) remodeling—the Glagovian phenomenon [34] by which a growing plaque expands outward into the adventitial space without compromising the lumen. A vessel with a normal luminal profile on ICA may therefore harbor a large, lipid-rich, vulnerable plaque within its wall. This blindness explains the well-documented poor correlation between angiographically mild stenoses and the anatomic location of subsequent lesiones culpables in acute coronary syndromes [46].

4.5 Comparative summary of imaging modalities

Table 1 summarizes the comparative technical specifications, resolution, and clinical utility of CCTA, IVUS/VH-IVUS, OCT, and ICA.

Modality	Physics	Axial Resolution	Penetration	Composition Assessment	Key Constraints
CCTA	X-ray attenuation	300–500 µm	Unlimited (non-invasive)	Low-attenuation plaque (<30 HU) as necrotic-core surrogate; spotty calcium; positive remodeling	Blooming artifact; radiation; iodinated contrast
IVUS / VH-IVUS	Acoustic backscatter (20–60 MHz)	100–200 µm	Full thickness to adventitia	Fibrotic, fibrofatty, dense calcium, necrotic core (radiofrequency classification)	Invasive; cannot resolve fibrous cap thickness <100 µm
OCT	Near-infrared light interferometry (~1300 nm)	10–20 µm	1–3 mm (shallow)	Fibrous cap thickness; macrophage infiltration; cholesterol crystals; neovascularization	Invasive; requires blood-clearance flush; cannot see EEM in lipid-rich plaque
ICA	2D X-ray fluoroscopy	~200 µm	None (visualizes lumen only)	None — luminal silhouette only	Invasive; blind to positive remodeling and plaque burden

4.6 Cross-modal harmonization: luminal silhouette vs. true plaque burden

Reconciling traditional angiographic narrowing with true volumetric plaque burden requires explicit accounting for compensatory remodeling. The remodeling index is defined as the ratio of the lesion-site EEM cross-sectional area to that of a proximal reference segment; a remodeling index greater than 1.05 denotes positive remodeling [34]. During early atherogenesis, the vessel wall expands outward to preserve luminal area until plaque burden exceeds a critical threshold—biophysical modeling places this transition closer to 50% plaque burden in vivo, rather than the 40% historically derived from ex vivo pressurized specimens.

Percent atheroma volume (PAV), the canonical IVUS endpoint, integrates lesion EEM and lumen areas across matched longitudinal segments and is mathematically immune to positive remodeling, exposing the true anatomic plaque burden masked by ICA. PAV is therefore the appropriate endpoint for serial regression trials, while ICA-derived percent diameter stenosis remains useful for revascularization planning.

4.7 Cross-modal harmonization: acoustic vs. optical resolution

The order-of-magnitude resolution disparity between IVUS (100–200 µm) and OCT (10–20 µm) introduces a systematic classification error for thin-cap fibroatheroma. Because the histologic TCFA threshold (<65 µm) lies below the axial resolution of IVUS, gray-scale and VH-IVUS cannot reliably distinguish a vulnerable thin cap from a stable thick cap [48]. IVUS will therefore systematically misclassify a TCFA as stable fibrous tissue.

Modern core laboratories address this resolution gap through co-registered, dual-modality acquisition: IVUS and OCT pullbacks are aligned at matched longitudinal landmarks (side branches, calcium deposits), and high-resolution OCT cap measurements are projected onto the broader IVUS-derived volumetric map. Combined IVUS-OCT catheters, now in late-stage clinical development, will eventually permit single-pullback acquisition with mathematically consistent registration.

4.8 Non-invasive extrapolation: CCTA to IVUS/OCT equivalencies

Establishing equivalency between non-invasive CCTA and invasive IVUS/OCT is essential for longitudinal regression tracking in patients for whom invasive imaging is impractical. AI-driven quantitative CT (AI-QCT) platforms have been validated against IVUS, achieving correlation coefficients of approximately 0.85–0.95 for external elastic membrane volume, lumen volume, and total plaque volume across multicenter cohorts [44,45]. Standardized algorithms map CCTA Hounsfield Unit density profiles to OCT-derived lipid arc and macrophage indices, with low-attenuation plaque volume serving as a credible non-invasive surrogate for IVUS-defined necrotic-core volume.

For longitudinal regression studies, the practical implication is that CCTA with AI-QCT analysis can replace repeated invasive imaging in the majority of patients, reserving IVUS or OCT for adjudicación of high-risk plaques, post-revascularization surveillance, or research-grade endpoint validation.

4.9 Artificial intelligence and core-laboratory standardization

Operator-dependent variability has historically constrained the reproducibility of intravascular imaging endpoints. Deep-learning architectures—spatial-temporal convolutional neural networks with SegNet backbones for OCT calcification segmentation, U-Net derivatives and generative adversarial networks (Pix2Pix GAN with ResNet backbones) for IVUS lumen and vessel-area segmentation—now achieve performance comparable to or exceeding expert manual annotation, with F1 scores in the 0.85–0.95 range and inter-operator variability reduced by an order of magnitude.

AI-driven segmentation also enables patient-as-own-control longitudinal designs: baseline and follow-up pullbacks are spatially co-registered using three-dimensional matching of calcified matrices and branch points, artifacts are mathematically subtracted, and absolute plaque-volume deltas are computed. This standardization has narrowed the noise floor of regression measurement to the point where 1–3% PAV change in matched segments can be reliably detected—roughly the magnitude of change demonstrated in GLAGOV [10] y PACMAN-AMI [11].

5. Lifestyle Interventions: Dietary and Exercise Paradigms

Intensive dietary and exercise interventions exert profound systemic physiological effects that translate into measurable changes in plaque composition, vascular biomarkers, and—in adequately powered trials—angiographic and intravascular imaging endpoints. The evidence base spans three principal traditions: the very low-fat plant-forward paradigm of Ornish and Esselstyn, the Mediterranean and DASH dietary patterns, and structured aerobic exercise (continuous and interval) protocols.

5.1 The Ornish paradigm and the Lifestyle Heart Trial

The Lifestyle Heart Trial, published by Ornish and colleagues in The Lancet in 1990 [20] with a five-year follow-up in JAMA in 1998 [21], remains the only ensayo controlado aleatorizado to demonstrate angiographic regression of coronary atherosclerosis using lifestyle modification alone, without lipid-lowering pharmacotherapy. The intervention combined a <10% fat whole-foods dieta vegetariana (excluding all animal products except egg whites and non-fat dairy), moderate aerobic exercise, group support, stress management, and fumar cessation.

At one-year follow-up of 28 randomized patients, quantitative coronary angiography demonstrated a regression of average percent diameter stenosis in the experimental group from 40.0% to 37.8%—a 2.2 percentage-point absolute reduction—while the control group progressed from 42.7% to 46.1% (between-group p<0.001) [20]. When analysis was restricted to severe lesions (≥50% baseline stenosis), the experimental group showed regression from 61.1% to 55.8%, while controls progressed from 61.7% to 64.4%.

Five-year follow-up extended these findings: the experimental group showed continued progressive regression to a mean stenosis of 34.7% (an absolute 7.9% reduction from pre-intervention baseline of 42.6%, or approximately 19% relative regression), while the control group progressed to 51.4% (an absolute 11.8% worsening from 39.6%) [21]. Angina frequency declined by 91% in the experimental group at one year and remained 72% below baseline at five years. Importantly, the experimental group experienced approximately 2.5-fold fewer eventos cardíacos over five years than the usual-care control group, providing rare lifestyle-only outcomes data.

5.1.1 The HDL-C paradox in very low-fat plant-forward diets

A central lipidological paradox of the Ornish paradigm is that profound plaque regression occurred despite a modest decrease in HDL-C and a modest elevation in fasting triglycerides—a perfil lipídico that would, in epidemiologic risk equations, be classified as adverse. The resolution of this paradox lies in the kinetics of HDL particle metabolism under isocaloric very low-fat versus Western dietary patterns.

Isotope-tracer studies by Brinton, Eisenberg, and Breslow [38] and Velez-Carrasco and colleagues [37] demonstrated that low-fat dietary restriction reduces HDL-C primarily by decreasing the apolipoprotein A-I (apoA-I) production rate—not by accelerating apoA-I clearance. Specifically, Velez-Carrasco et al. showed that a low-fat diet reduced apoA-I production by approximately 25%, while the fractional catabolic rate remained essentially unchanged. In contrast, the low HDL-C of metabolic syndrome and Western-diet patterns is driven by accelerated HDL particle clearance and hypercatabolism.

Because diet-induced low HDL-C reflects a downregulated, kinetically efficient transporte inverso de colesterol system rather than catabolic dysfunction, it does not carry the same atherogenic risk as Western-diet-induced low HDL-C. This is the most plausible mechanistic explanation for the observation that profound plaque regression in Ornish-paradigm cohorts coexists with modest HDL-C reductions, and it illustrates why population-derived risk equations can produce misleading inferences when applied to individuals on profoundly altered dietary backgrounds.

Esselstyn’s longitudinal case series [36,50], while not randomized, extends the Ornish-paradigm evidence base to longer follow-up and to patients with more severe pre-intervention disease, including those who declined or had failed conventional revascularization. Across decades of follow-up, sustained adherencia to a strict whole-food plant-based dietary pattern was associated with arrest and frequently regression of disease, and with extremely low rates of recurrent cardiac events. The case-series design precludes causal inference, but the consistency with the randomized Lifestyle Heart Trial supports the dietary paradigm as biologically credible.

5.2 DASH and Mediterranean dietary patterns

The DASH (Dietary Approaches to Stop Hipertensión) and Mediterranean dietary patterns provide a less restrictive, more readily adoptable alternative to the very low-fat plant-forward approach. Both emphasize plant foods, whole grains, legumes, and fish; both restrict alimentos ultraprocesados, refined carbohidratos, y carne roja; both have been extensively validated for presión arterial, lipid, and cardiovascular outcomes in large cohorts.

The DISCO-CT trial [35] randomized patients with non-obstructive coronary atherosclerosis (CCTA-defined plaque present without obstructive stenosis) to optimal medical therapy alone or to OMT plus a dietitian-led intensive DASH-style intervention. During the 12-month active phase, the intervention arm achieved a mean pérdida de peso of approximately 3.8 kg, total body fat reduction of approximately 2.4%, and a clinically significant reduction in circulating CXCL4 from approximately 2,300 pg/mL to 1,900 pg/mL (p<0.05).

Six years after cessation of active coaching, the intervention cohort had regained most of the lost body weight and body fat and showed increased visceral adipose tissue, consistent with the well-documented rebound dynamics of dietary interventions. Despite this anthropometric rebound, CXCL4 remained suppressed below pre-intervention baseline values, while CXCL4 in the control group continued to rise over time. Dietary adherence scores in the intervention arm also remained 22 points higher than control at six-year follow-up. The cumulative incidence of MACE was 1 event in the intervention arm versus 4 in the control arm over 6 years (p not statistically significant given limited event count, but consistent with effect direction).

The DISCO-CT data illustrate two principles. First, the most durable benefits of dietary intervention may be encoded in vascular biology (chemokine and endothelial reprogramming) rather than in body composition, which rebounds readily. Second, the effect sizes achievable with a real-world dietary intervention in non-obstructive coronary disease, while not as dramatic as those documented in the Ornish protocol, are clinically meaningful and reproducible at the multicenter scale.

5.3 Aerobic exercise: high-intensity interval training and moderate continuous training

The direct vascular impact of structured exercise has been quantified using gray-scale and radiofrequency IVUS in randomized comparisons of entrenamiento en intervalos de alta intensidad (HIIT) against moderate continuous training (MCT). The landmark trial of Madssen and colleagues [27] randomized 36 patients with stable coronary disease following percutaneous coronary intervention to a 12-week supervised exercise program—either HIIT (4 × 4-minute intervals at 85–95% of peak frecuencia cardíaca, twice weekly) or MCT (continuous aerobic exercise at 70–75% of peak heart rate, twice weekly)—followed by 12 months of home-based exercise.

Across matched IVUS segments at 12-month follow-up, both HIIT and MCT produced significant regression in normalized total atheroma volume (TAVnorm) compared with baseline. The combined exercise cohorts demonstrated reduction in necrotic core fraction and stabilization of plaque composition, with no clear superiority of HIIT over MCT in volumetric endpoints. The trial established that structured supervised aerobic exercise, independent of diet, produces measurable structural improvement at the level of the arterial wall.

The systemic physiological mechanisms linking exercise to vascular benefit are multiple and additive:

Shear-stress-induced eNOS upregulation. Sustained laminar shear stress during exercise upregulates endothelial nitric oxide synthase via KLF2-mediated transcription, restoring vasodilatory capacity and reducing monocyte adhesion.

Mobilization of células progenitoras endoteliales. Exercise stimulates bone-marrow-derived progenitor cell mobilization, supporting endothelial monolayer repair and re-endothelialization.

Upregulation of antioxidante defense enzymes. Regular exercise upregulates—not downregulates, as is sometimes erroneously claimed—the activity of superoxide dismutase (SOD), catalase, and glutathione peroxidase in the vascular wall, reducing the rate of subendothelial LDL oxidation and the generation of reactive oxygen species.

Anti-inflammatory cytokine reprogramming. Skeletal muscle contraction induces release of IL-6 with anti-inflammatory (rather than pro-inflammatory) downstream signaling, with associated reductions in TNF-α and CRP.

Metabolic reprogramming. Improvements in sensibilidad a la insulina, lipid oxidation, and grasa visceral reduction collectively reduce systemic and vascular substrate for atherogenesis.

5.4 Comparative summary of lifestyle interventions

Table 2 compares the principal lifestyle paradigms by intervention intensity, volumetric and angiographic endpoints, biomarker effects, hard cardiovascular outcomes, and adherence durability.

Paradigm	Volumetric/Angiographic Δ	Biomarker Δ	Hard Outcomes (MACE)	Adherence/Durability
Lifestyle Heart Trial / Ornish [20,21]	Angiographic regression: −2.2% diameter stenosis at 1 yr; −7.9% absolute at 5 yr; severe-lesion regression −5.3% at 1 yr	LDL-C −40% at 1 yr; HDL-C slight ↓ (kinetic, not adverse); reduced apoA-I production rate	~2.5× fewer cardiac events at 5 yr in experimental vs. control	High under supervised trial conditions; lower in unsupervised real-world deployment
DISCO-CT (DASH-style) [35]	Non-obstructive plaque stabilization on CCTA	Sustained CXCL4 suppression at 6 yr; ↓ weight and body fat during active phase with rebound thereafter	1 vs. 4 MACE over 6 yr (effect direction consistent; underpowered for significance)	Active coaching produces durable biomarker effect even after anthropometric rebound
HIIT exercise [27]	↓ TAVnorm; ↓ necrotic core fraction in matched segments	↑ condición cardiorrespiratoria; ↓ inflammatory markers; ↑ eNOS/KLF2 vascular program	Reduced events in combined exercise cohorts; small samples	Requires structured/supervised reinforcement for durability
MCT exercise	↓ TAVnorm; stabilization of plaque composition	Modest fitness gains; comparable plaque-stabilization effect to HIIT	Reduced events in combined exercise cohorts	Higher real-world adherence than HIIT; lower CRF improvement

6. Pharmacotherapy: Lipid, Inflammatory, and Metabolic Axes

Contemporary pharmacotherapy for atherosclerosis regression is no longer a single-axis intervention. The evidence base now supports simultaneous targeting of (1) apoB-particle production and clearance, (2) cholesterol absorption and ATP-citrate lyase, (3) PCSK9-mediated receptor de LDL degradation, (4) the IL-1β/IL-6 inflammatory pathway, (5) the NLRP3 inflammasome, (6) hypertriglyceridemia and the membrane stabilization axis, (7) lipoprotein(a), and (8) metabolic risk through SGLT2 and GLP-1 modulation. The following subsections review the evidence for each axis.

6.1 Statins: foundation of LDL-lowering pharmacotherapy

3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) remain the foundational lipid-lowering agents. The Cholesterol Treatment Trialists’ (CTT) Collaboration meta-analyses [1,2] established the canonical relación dosis-respuesta: each 1 mmol/L (≈39 mg/dL) absolute reduction in LDL-C reduces major vascular events by approximately 22% (rate ratio 0.78, 95% CI 0.76–0.80) over an average of 5 years. The benefit accumulates with time: relative risk reduction is approximately 11% in the first year of therapy but rises to approximately 24% per year thereafter, reflecting the time required for plaque biology to remodel under sustained lipid pressure.

The serial-IVUS statin trials mapped this dosis-respuesta onto plaque biology. REVERSAL [7] compared pravastatina 40 mg (achieved LDL-C 110 mg/dL) against atorvastatina 80 mg (achieved LDL-C 79 mg/dL) over 18 months; the moderate-intensity arm showed progression in PAV, while the high-intensity arm halted progression. ASTEROID [8], using rosuvastatin 40 mg daily over 24 months in 349 patients, achieved a mean LDL-C of 60.8 mg/dL and demonstrated significant regression: PAV decreased by 0.79% (median; p<0.001 vs. baseline) and TAV decreased by 6.8% (mean −14.7 mm³; p<0.001), with regression observed in approximately 64% of patients. SATURN [9] compared rosuvastatin 40 mg and atorvastatin 80 mg head-to-head over 104 weeks in 1,039 patients, demonstrating comparable regression (PAV change −1.22% rosuvastatin vs. −0.99% atorvastatin; p=0.17), establishing the two agents as equivalent high-intensity backbones.

Mechanistically, estatina de alta intensidad therapy alters plaque composition beyond simple lipid removal. Statins promote conversion of spotty calcification to dense macrocalcificación—’cristalización de placa’—which mechanically splints the lesion against shear-stress-induced rupture, even when absolute volume reductions are modest. The PARADIGM registry [44] documented this composition shift at population scale: statin-treated patients showed slower progression of total plaque volume but accelerated conversion of non-calcified plaque (the rupture-prone substrate) to calcified plaque (the stable substrate).

6.2 PCSK9 inhibitors: monoclonal antibody-based ultra-low LDL achievement

Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds the hepatic LDL receptor and targets it for lysosomal degradation. Inhibition of PCSK9 with the monoclonal antibodies evolocumab and alirocumab restores hepatic LDL receptor recycling, reducing circulating LDL-C by an additional 50–60% on top of maximally tolerated statin therapy.

FOURIER [3], the largest cardiovascular outcomes trial of evolocumab, randomized 27,564 patients with stable atherosclerotic cardiovascular disease and LDL-C ≥70 mg/dL on statin therapy to evolocumab 140 mg every 2 weeks (or 420 mg monthly) or placebo. Evolocumab reduced LDL-C from a baseline of 92 mg/dL (2.4 mmol/L) to 30 mg/dL (0.78 mmol/L)—a 59% relative reduction—and lowered the composite primary endpoint of cardiovascular death, myocardial infarction, derrame cerebral, hospitalization for angina inestable, or coronary revascularization by 15% (HR 0.85, 95% CI 0.79–0.92, p<0.001) over a median follow-up of 2.2 years. The key secondary endpoint (cardiovascular death, MI, or stroke) was reduced by 20% (HR 0.80, 95% CI 0.73–0.88, p<0.001). Consistent with CTT-based time-dependence, event reduction was greater beyond the first year (24% reduction) than within it (12%).

ODYSSEY OUTCOMES [4] randomized 18,924 patients 1–12 months post-acute coronary syndrome to alirocumab (75 mg every 2 weeks, titratable to 150 mg) or placebo on a background of high-intensity statin therapy. Over a median follow-up of 2.8 years, alirocumab reduced the composite MACE endpoint by 15% (HR 0.85, 95% CI 0.78–0.93, p<0.001) and produced a nominally significant 15% reduction in all-cause mortality (HR 0.85, 95% CI 0.73–0.98, p=0.026). The absolute benefit was most pronounced in patients with baseline LDL-C ≥100 mg/dL, where the number needed to treat for MACE prevention was approximately 29 over 4 years.

Serial-IVUS confirmation came from GLAGOV [10], which randomized 968 statin-treated patients to evolocumab or placebo for 18 months. Evolocumab lowered LDL-C from a baseline of 92.5 mg/dL to a mean of 36.6 mg/dL and reduced PAV by an absolute 0.95% versus an increase of 0.05% with placebo (between-group difference −1.0%, p<0.001). Regression was observed in 64.3% of evolocumab-treated patients versus 47.3% of placebo-treated patients (p<0.001). In patients with baseline LDL-C <70 mg/dL, regression was achieved in over 80% of evolocumab-treated subjects.

PACMAN-AMI [11] extended this evidence to the acute coronary syndrome population, randomizing 300 patients within 24 hours of acute MI to alirocumab 150 mg every 2 weeks or placebo on a background of high-intensity rosuvastatin 20 mg. At 52 weeks, multimodality intravascular imaging of non-infarct-related arteries demonstrated approximately twofold greater regression of PAV in the alirocumab arm (−2.13% vs. −0.92%, between-group difference −1.21%, p<0.001), an increase in minimum fibrous cap thickness measured by OCT (62.7 µm in alirocumab vs. 33.2 µm in placebo, between-group difference +29.5 µm, p<0.001), and a significant reduction in maximum lipid core burden index by NIRS (between-group difference −41.2, p=0.01).

6.3 Ezetimibe: cholesterol absorption inhibition

Ezetimibe inhibits the Niemann-Pick C1-like 1 (NPC1L1) intestinal cholesterol transporter, reducing dietary and biliary cholesterol absorption and lowering LDL-C by approximately 15–25% on a statin background. The IMPROVE-IT trial demonstrated that adding ezetimibe 10 mg to simvastatin 40 mg in 18,144 post-ACS patients reduced the composite primary endpoint by 6.4% (HR 0.94, 95% CI 0.89–0.99, p=0.016) over 7 years—a modest but statistically significant validation of the LDL hypothesis at the lower end of achievable LDL-C levels.

PRECISE-IVUS [39] used serial IVUS to assess plaque effects: 246 patients undergoing percutaneous coronary intervention were randomized to atorvastatin alone (titrated to LDL-C <70 mg/dL) or atorvastatin plus ezetimibe 10 mg daily over 9–12 months. Dual therapy achieved lower mean LDL-C levels (63 mg/dL vs. 73 mg/dL) and significantly greater PAV regression (−1.4% vs. −0.3%, p=0.001), with a higher proportion of patients showing regression (78% vs. 58%, p=0.004). PRECISE-IVUS established combined synthesis-plus-absorption inhibition as a clinically synergistic strategy.

6.4 Bempedoic acid: ATP-citrate lyase inhibition

Bempedoic acid is a small-molecule profármaco that, after activation by very-long-chain acyl-CoA synthetase 1 (ACSVL1) in the liver, inhibits ATP-citrate lyase—the enzyme immediately upstream of Reductasa de la HMG-CoA in the cholesterol biosynthesis pathway. Because ACSVL1 is not expressed in skeletal muscle, bempedoic acid does not produce statin-associated muscle symptoms, making it particularly suited to statin-intolerant patients. Bempedoic acid lowers LDL-C by 15–25% as monotherapy and by an additional ~38% when combined with ezetimibe.

Resultados CLEAR [16], published in the New England Journal of Medicine in 2023, randomized 13,970 statin-intolerant patients with established cardiovascular disease or at high risk to bempedoic acid 180 mg daily or placebo. Over a median follow-up of 40.6 months, bempedoic acid reduced the composite primary endpoint (cardiovascular death, non-fatal MI, non-fatal stroke, or coronary revascularization) by 13% (HR 0.87, 95% CI 0.79–0.96, p=0.004). The trial established a credible cardiovascular outcomes benefit for an oral, non-statin LDL-lowering agent in the statin-intolerant population, while observing no significant reduction in all-cause mortality.

6.5 Inclisiran: small interfering RNA targeting hepatic PCSK9

Inclisiran is a hepatocyte-directed small interfering RNA (siRNA) that silences PCSK9 mRNA, thereby reducing hepatic PCSK9 synthesis and increasing LDL receptor density. Administered as a single subcutaneous injection at baseline, month 3, and every 6 months thereafter, inclisiran achieves durable LDL-C reductions of approximately 50% with biannual dosing—a substantial improvement in dosing convenience compared with biweekly monoclonal antibody therapy.

ORION-10 and ORION-11 [17], published together in the New England Journal of Medicine in 2020, randomized 1,561 and 1,617 patients respectively with atherosclerotic cardiovascular disease (ORION-10) or ASCVD-equivalent risk (ORION-11) and elevated LDL-C on maximally tolerated statin therapy to inclisiran or placebo. At day 510, inclisiran reduced LDL-C by 52.3% in ORION-10 (95% CI −55.7 to −48.8) and 49.9% in ORION-11 (95% CI −53.1 to −46.6) compared with placebo. Treatment-emergent adverse events were generally mild and included injection-site reactions. The pending ORION-4 outcomes trial is testing whether the imaging-validated LDL reduction translates into cardiovascular event reduction comparable to the PCSK9 monoclonal antibodies.

6.6 Lipoprotein(a)-directed therapies

Lipoprotein(a) [Lp(a)] is an LDL-like particle to which apolipoprotein(a)—a plasminogen-homologous protein—is covalently attached. Elevated Lp(a) is an independent, causal, genetically determined cardiovascular factor de riesgo: Aleatorización mendeliana studies and large cohortes prospectivas have established that lifetime exposure to elevated Lp(a) increases coronary event risk in a dose-dependent fashion, while pharmacologic LDL-lowering reduces but does not eliminate Lp(a)-driven risk. Until recently, no targeted therapy was available; statins do not lower Lp(a), and PCSK9 inhibitors lower Lp(a) only modestly (15–25%).

Pelacarsen (TQJ230) is an antisense oligonucleotide targeting apolipoprotein(a) mRNA. The phase 2 trial published by Tsimikas and colleagues in the New England Journal of Medicine in 2020 [18] demonstrated dose-dependent reductions in Lp(a) of up to 80% with weekly subcutaneous dosing, with peak placebo-corrected reductions exceeding 90% at the highest dose tier. The Lp(a)HORIZON outcomes trial (NCT04023552), enrolling patients with established cardiovascular disease and elevated Lp(a), is testing whether this profound molecular reduction translates into cardiovascular event reduction.

Olpasiran is a small interfering RNA targeting LPA mRNA. The phase 2 OCEAN(a)-DOSE trial published by O’Donoghue and colleagues in the New England Journal of Medicine in 2022 [19] demonstrated placebo-corrected Lp(a) reductions of 70.5% to 101% across dose tiers, with the effect sustained for months following each subcutaneous injection. The OCEAN(a)-Outcomes phase 3 trial is ongoing.

If positive, the Lp(a)HORIZON and OCEAN(a)-Outcomes trials will validate the first pharmacologic strategy to address an atherogenic lipoprotein previously regarded as genetically immutable. This would have major implications for the residual-risk framework: roughly 20% of the population has Lp(a) levels above the clinically actionable threshold (50 mg/dL or 125 nmol/L), and a large fraction of patients with optimally treated LDL-C continue to experience events that may be attributable to elevated Lp(a).

6.7 Purified omega-3 fatty acids: icosapent ethyl

Targeting non-LDL riesgo residual, the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (REDUCE-IT) [6] randomized 8,179 statin-treated patients with persistent hypertriglyceridemia (150–499 mg/dL) and established cardiovascular disease or diabetes plus risk factors to icosapent ethyl (IPE) 4 g daily or mineral-oil placebo. Over a median follow-up of 4.9 years, IPE reduced the composite primary endpoint by 25% (HR 0.75, 95% CI 0.68–0.83, p<0.001) and the key secondary endpoint of cardiovascular death, MI, or stroke by 26% (HR 0.74, 95% CI 0.65–0.83, p<0.001). The total event analysis showed a 30% reduction in total ischemic events (RR 0.70, 95% CI 0.62–0.78, p<0.001).

The serial-CCTA validation came from EVAPORATE [22], which randomized 80 patients with elevated triglycerides (135–499 mg/dL) on statin therapy to IPE 4 g daily or placebo over 18 months. IPE produced a 17% relative reduction in low-attenuation plaque volume (primary endpoint, p<0.01), while placebo showed 109% progression of LAP volume. Significant favorable effects were also observed for total non-calcified plaque (−19%), fibrofatty plaque (−34%), and fibrous plaque (−20%), with no significant progression of calcified plaque, consistent with a stabilization signature.

CHERRY [23] confirmed these findings invasively, using integrated backscatter IVUS to evaluate eicosapentaenoic acid 1,800 mg added to pitavastatina 4 mg in stable coronary disease over 6–8 months. The EPA/statin combination significantly reduced total atheroma volume and selectively decreased the lipid component compared with statin monotherapy, particularly in patients with stable angina.

Mechanistically, EPA stabilizes membrane structure through direct incorporation into phospholipid bilayers, restores función endotelial, reduces oxidative stress and platelet activation, and exerts anti-inflammatory effects independent of LDL-C lowering. The REDUCE-IT findings and mechanism are not fully replicated by docosahexaenoic acid (DHA)-containing omega-3 formulations, suggesting an EPA-specific molecular signature. A controversy surrounding REDUCE-IT concerns the mineral-oil placebo, which may have caused modest adverse effects in the comparator arm, potentially exaggerating the apparent benefit of IPE; this concern has not been definitively resolved and represents an ongoing limitation of the evidence base.

6.8 Anti-inflammatory therapy: canakinumab and colchicine

CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcome Study) [15] tested the inflammatory hypothesis of atherothrombosis directly. The trial randomized 10,061 patients with prior MI and hsCRP ≥2 mg/L to canakinumab—a monoclonal antibody targeting IL-1β—at 50, 150, or 300 mg subcutaneously every 3 months, or placebo. The 150-mg dose reduced the primary endpoint (non-fatal MI, non-fatal stroke, or cardiovascular death) by 15% (HR 0.85, 95% CI 0.74–0.98, p=0.021) over a median follow-up of 3.7 years, while reducing hsCRP by approximately 37% with no effect on LDL-C. The cardiovascular benefit was concentrated in patients who achieved on-treatment hsCRP <2 mg/L, supporting a causal inflammatory pathway from IL-1β through IL-6 through hsCRP.

CANTOS provided the first definitive proof that anti-inflammatory therapy reduces cardiovascular events independent of lipid lowering, validating the residual inflammatory risk concept [42,43]. However, canakinumab also produced a small but significant increase in fatal infections, and the drug is not currently approved for atherosclerosis indications. The conceptual victory of CANTOS lies in establishing the inflammatory pathway as a tractable, separately drugable target—a victory that has since been extended through colchicine.

Colchicine inhibits microtubule polymerization, preventing NLRP3 inflammasome assembly in monocytes and macrophages, reducing IL-1β and IL-6 maturation, and lowering hsCRP. Three landmark trials established its cardiovascular efficacy:

COLCOT [13] randomized 4,745 patients within 30 days of an acute MI to colchicine 0.5 mg daily or placebo. Over a median follow-up of 22.6 months, colchicine reduced the composite primary endpoint of cardiovascular death, resuscitated paro cardíaco, MI, stroke, or urgent coronary revascularization for angina by 23% (HR 0.77, 95% CI 0.61–0.96, p=0.02).

LoDoCo2 [14] randomized 5,522 patients with stable chronic coronary disease to colchicine 0.5 mg daily or placebo. Over a median follow-up of 28.6 months, colchicine reduced the composite primary endpoint by 31% (HR 0.69, 95% CI 0.57–0.83, p<0.001), with consistent reductions across non-fatal MI, infarto isquémico, and ischemia-driven revascularization.

COLOCT [12], published in Circulación in 2024, used serial OCT to test whether colchicine produces structural plaque stabilization. The trial enrolled ACS patients with OCT-defined lipid-rich plaques (lipid arc >90°) and randomized them to colchicine 0.5 mg daily added to maximally tolerated lipid-lowering therapy or to optimal therapy alone. At 12-month follow-up, colchicine significantly increased minimum fibrous cap thickness compared with control (between-group difference approximately +40–50 µm, depending on the segment analyzed), reduced average lipid arc (Δ ≈ −31° in the colchicine arm, medium-confidence pending primary-source verification), reduced macrophage accumulation, and reduced the incidence of OCT-defined TCFA—providing the structural mechanism for the clinical event reductions documented in COLCOT and LoDoCo2.

Colchicine’s principal limitations are gastrointestinal intolerance (diarrhea, abdominal cramping) in approximately 5–10% of patients, contraindication in advanced renal or hepatic dysfunction, and pharmacokinetic interactions with strong CYP3A4 inhibitors and P-glycoprotein substrates. Within these constraints, low-dose colchicine has emerged as a deployable, inexpensive, orally bioavailable anti-inflammatory complement to lipid-lowering therapy.

6.9 Residual inflammatory risk: hsCRP as a parallel treatment target

The collective evidence from CANTOS, JUPITER, COLCOT, LoDoCo2, and COLOCT supports a clinical framework in which residual inflammatory risk—defined as persistently elevated hsCRP despite optimal LDL-C lowering—is a parallel and additive target alongside residual cholesterol risk [42,43]. The collaborative analysis by Ridker, Bhatt, and colleagues in The Lancet in 2023 [43] pooled data from three randomized trials of statin therapy and demonstrated that residual inflammatory risk (hsCRP ≥2 mg/L on statin) was a stronger predictor of recurrent events than residual cholesterol risk (LDL-C levels) in patients with achieved LDL-C below 70 mg/dL.

Operationally, this argues for hsCRP measurement after lipid optimization, and for the addition of low-dose colchicine in patients whose hsCRP remains elevated despite maximally tolerated lipid-lowering therapy. The exact hsCRP threshold for intervention remains a matter of clinical judgment; values consistently >2 mg/L after exclusion of acute illness, autoimmune disease, and active infection are most commonly cited.

6.10 SGLT2 inhibitors and GLP-1 receptor agonists

Two classes of glucose-lowering therapy have demonstrated cardiovascular benefit independent of control glucémico, with mechanistic actions that overlap with—and complement—the lipid and inflammatory axes.

inhibidores de SGLT2 (empagliflozin, canagliflozin, dapagliflozin) block proximal-tubule glucosa and sodium reabsorption, producing modest glucose lowering, osmotic diuresis, and pleiotropic vascular effects including improved endothelial function, reduced vascular cell adhesion molecule expression, suppression of NLRP3 inflammasome activation, and preservation of the glicocáliz endotelial. EMPA-REG OUTCOME [26] randomized 7,020 patients with type 2 diabetes and established cardiovascular disease to empagliflozin or placebo and demonstrated a 14% reduction in MACE (HR 0.86, 95% CI 0.74–0.99, p=0.04), a 38% reduction in cardiovascular death (HR 0.62, 95% CI 0.49–0.77, p<0.001), and a 35% reduction in insuficiencia cardíaca hospitalization.

agonistas del receptor de GLP-1 (liraglutide, semaglutida, dulaglutide) augment glucose-dependent insulina secretion, suppress glucagon, slow gastric emptying, and produce centrally mediated saciedad. Mechanistically relevant to atherosclerosis are anti-inflammatory effects, improvement in endothelial function, suppression of macrophage activation, and substantial weight reduction. LEADER [24] (liraglutide, 9,340 patients) demonstrated a 13% reduction in MACE (HR 0.87, 95% CI 0.78–0.97, p=0.01) and a 22% reduction in cardiovascular death over 3.8 years. SUSTAIN-6 [25] (semaglutide, 3,297 patients) demonstrated a 26% MACE reduction (HR 0.74, 95% CI 0.58–0.95, p=0.02), with particular benefit for non-fatal stroke.

Preliminary serial-CCTA data in diabetic patients early post-acute coronary syndrome have demonstrated significant plaque regression with GLP-1 receptor agonists added to standard lipid-lowering therapy, driven by favorable composition changes in non-calcified and fibrofatty plaque. While GLP-1 RAs and SGLT2 inhibitors are not first-line agents in non-diabetic ASCVD populations, their inclusion is appropriate in any patient with type 2 diabetes, established CVD, or metabolic syndrome with high vascular risk.

6.11 Comparative summary of pharmacologic axes

Table 3 summarizes the principal pharmacologic agents reviewed, their mechanistic axis, lipid and inflammatory effects, imaging-validated structural changes, hard cardiovascular outcomes, and principal safety considerations.

Drug Class / Agent	Benchmark Trial(s)	LDL/apoB Δ	Imaging Δ	MACE Reduction	Principal Side Effects
High-intensity statins (rosuvastatin 40, atorvastatin 80)	ASTEROID [8], SATURN [9], REVERSAL [7]	LDL-C achieved 60–80 mg/dL	PAV regression 0.5–1.2%; promotes plaque calcification (stabilization)	~22% per 1 mmol/L LDL-C reduction (CTT) [1,2]	Myalgias (5–10%); transaminitis; mild new-onset diabetes risk
PCSK9 inhibitors (evolocumab, alirocumab)	FOURIER [3], ODYSSEY OUTCOMES [4], GLAGOV [10], PACMAN-AMI [11]	Additional 50–60% LDL-C reduction; achieved 25–40 mg/dL	PAV regression ~1.0–2.1%; FCT thickening +29.5 µm (PACMAN-AMI)	15% (HR 0.85) on top of statin; 15% all-cause mortality reduction in ODYSSEY	Injection-site reactions; rare neurocognitive concerns not confirmed
Ezetimiba	IMPROVE-IT; PRECISE-IVUS [39]	Additional 15–25% LDL-C reduction	PAV regression −1.4% with statin combo	6.4% (HR 0.94) on top of simvastatin in IMPROVE-IT	Well tolerated; mild GI
Ácido bempedoico	Resultados CLEAR [16]	15–25% monotherapy; ~38% combined with ezetimibe	Not yet imaging-validated for regression	13% (HR 0.87, p=0.004) in statin-intolerant	Hiperuricemia; tendon rupture (rare); no muscle symptoms
Inclisirán (ARNm de interferencia)	ORION-10/11 [17]	~50% LDL-C reduction with biannual dosing	Outcomes pending (ORION-4)	Pending	Mild injection-site reactions
Lp(a) ASO (pelacarsen)	Tsimikas et al. NEJM 2020 [18]	Up to 80% Lp(a) reduction; no LDL-C effect	Outcomes pending (Lp(a)HORIZON)	Pending	Mild injection-site reactions
Lp(a) siRNA (olpasiran)	OCEAN(a)-DOSE [19]	Up to 101% Lp(a) reduction; no LDL-C effect	Outcomes pending (OCEAN(a)-Outcomes)	Pending	Mild injection-site reactions
Icosapent ethyl (EPA)	REDUCE-IT [6], EVAPORATE [22], CHERRY [23]	No LDL-C change	LAP volume −17%; fibrofatty plaque −34%	25% (HR 0.75, p<0.001) in REDUCE-IT	Fibrilación auricular (small absolute increase); mild bleeding
Canakinumab (anti-IL-1β)	CANTOS [15]	No LDL-C change; hsCRP −37%	Not directly imaged in CANTOS	15% (HR 0.85, p=0.021) for 150-mg dose	Modest increase in fatal infections
Colchicine (NLRP3 inhibition)	COLCOT [13], LoDoCo2 [14], COLOCT [12]	No LDL-C change	FCT thickening; lipid arc reduction (COLOCT)	23% (COLCOT), 31% (LoDoCo2) MACE reduction	GI intolerance; CYP3A4 interactions
SGLT2 inhibitors (empagliflozin)	EMPA-REG OUTCOME [26]	Minimal lipid effect	Microvascular preservation; HF prevention	14% MACE; 38% CV death; 35% HF hospitalization	Genital mycotic infection; euglycemic DKA (rare)
GLP-1 RAs (liraglutide, semaglutide)	LEADER [24], SUSTAIN-6 [25]	Modest lipid improvements; weight loss	Non-calcified plaque regression (preliminary CCTA)	13% MACE (LEADER); 26% (SUSTAIN-6)	Nausea; vomiting; rare pancreatitis

7. Synthesis: A Multi-Pathway Combination Protocol for Atherosclerosis Regression

The evidence reviewed in Sections 3 through 6 supports a coordinated, multi-axis therapeutic strategy that addresses atherogenesis at every stage of its biological cycle: lipoprotein retention, endothelial activation, monocyte recruitment, inflammasome activation, residual lipoprotein and inflammatory risk, and metabolic substrate. No single pharmacologic axis—however potent—is sufficient. The clinical opportunity lies in the rational, sequential, and individualized integration of these axes.

This section synthesizes the prior evidence into an operational framework organized around five therapeutic levers. Each lever has its own validated target, its own benchmark trial(s), and its own monitoring biomarker. The protocol is designed to be deployed in tiers, with intensity matched to baseline risk and to interval response.

7.1 Five-lever framework

Lever 1 — apoB-particle reduction. The foundation of all regression strategies. Target LDL-C and apoB to levels well below contemporary guideline minima, recognizing the log-linear, ceiling-free relationship between achieved apoB and event reduction [1,2,3,4]. Suggested targets by risk tier:

Established ASCVD with recurrent events: LDL-C <40 mg/dL, apoB <50 mg/dL
Established ASCVD without recurrent events: LDL-C <55 mg/dL, apoB <65 mg/dL
High-risk prevención primaria (CAC >100 or strong historial familiar): LDL-C <70 mg/dL, apoB <80 mg/dL
Standard primary prevention: LDL-C <100 mg/dL, apoB <90 mg/dL

Sequential deployment: high-intensity statin first; add ezetimibe if not at target; add PCSK9 inhibitor (or inclisiran for dosing convenience) if still not at target; consider bempedoic acid in statin-intolerant patients.

Lever 2 — Inflammatory pathway inhibition. Target persistent hsCRP elevation despite optimal LDL-C control. The CANTOS, COLCOT, LoDoCo2, and COLOCT trials [12–15] support low-dose colchicine 0.5 mg daily as the principal deployable agent. Target on-treatment hsCRP <2 mg/L. Canakinumab, while definitively validated mechanistically, is not currently approved for atherosclerosis indications and is therefore not part of routine clinical practice.

Lever 3 — Triglyceride-rich lipoprotein and membrane stabilization. In statin-treated patients with persistent hypertriglyceridemia (150–499 mg/dL), add icosapent ethyl 4 g daily, as validated by REDUCE-IT [6] and EVAPORATE [22]. Target serum EPA elevation; triglycerides per se are a marker, not the principal mechanism.

Lever 4 — Metabolic axis. In patients with type 2 diabetes, established cardiovascular disease, or metabolic syndrome with high vascular risk, deploy SGLT2 inhibitors and/or GLP-1 receptor agonists per LEADER [24], SUSTAIN-6 [25], and EMPA-REG OUTCOME [26]. The cardiovascular benefit is independent of glycemic control and is mechanistically additive to lipid and inflammatory targeting.

Lever 5 — Lifestyle reinforcement. Plant-forward dietary pattern (Lifestyle Heart Trial / DASH / Mediterranean [20,21,35]) plus structured aerobic exercise (HIIT or MCT [27]) plus sleep and stress management plus complete smoking cessation. Lifestyle modifies—and may catalyze—the biological effect of pharmacotherapy through additive mechanisms: shear-stress vascular reprogramming, antioxidant defense upregulation, anti-inflammatory cytokine reprogramming, CXCL4 suppression [35], and improved insulin sensitivity.

7.2 Numeric targets by risk tier

Table 4 specifies operational targets across the five levers, stratified by clinical risk tier.

Risk Tier	LDL-C / apoB	PCRat	Triglycerides / EPA	Metabolic	Lifestyle
Recurrent-event ASCVD	LDL <40 / apoB <50	<2 mg/L (add colchicine 0.5 mg)	TG <150 (add IPE 4 g if elevated)	SGLT2i + GLP-1 RA if diabetic or metabolic syndrome	Plant-forward diet; supervised HIIT; smoking cessation
Established ASCVD	LDL <55 / apoB <65	<2 mg/L	TG <150 (add IPE 4 g if elevated)	SGLT2i + GLP-1 RA per indication	Mediterranean/DASH; structured aerobic exercise
High-risk primary (CAC >100 or strong FH)	LDL <70 / apoB <80	<2 mg/L (consider colchicine)	TG <150	SGLT2i if diabetic	Plant-forward diet; structured exercise
Standard primary	LDL <100 / apoB <90	<2 mg/L (lifestyle first)	TG <150	Per glycemic indication	Mediterranean dietary pattern; ≥150 min/wk moderate exercise

7.3 Sequential deployment and treatment escalation

The protocol is operationalized as a decision-tree approach to escalation, monitored at 3-month intervals during the active titration phase and 6–12 month intervals thereafter:

Baseline assessment. Lipid panel including LDL-C, non-HDL-C, apoB, Lp(a) (once-in-a-lifetime), hsCRP, HbA1c, complete metabolic panel, CCTA or CAC scoring per indication. Document baseline lifestyle pattern, smoking status, and metabolic comorbidities.
High-intensity statin (rosuvastatin 40 mg or atorvastatin 80 mg) plus structured lifestyle intervention (plant-forward dietary counseling and supervised aerobic exercise program). For patients with documented statin intolerance, initiate bempedoic acid plus ezetimibe.
3-month reassessment. Repeat lipid panel and hsCRP. If LDL-C remains above tier target, add ezetimibe 10 mg. If apoB remains discordantly elevated relative to LDL-C, consider apoB-anchored escalation.
6-month reassessment. If LDL-C remains above tier target on statin + ezetimibe, add PCSK9 inhibitor (evolocumab 140 mg q2 weeks, alirocumab 75–150 mg q2 weeks) or inclisiran (initial dose, month 3 dose, then q6 monthly). If hsCRP remains ≥2 mg/L after exclusion of intercurrent inflammation, add colchicine 0.5 mg daily. If triglycerides remain ≥150 mg/dL despite optimal statin, add IPE 4 g daily.
12-month reassessment. Re-image with CCTA or non-invasive plaque-burden modality as available; assess composition changes (LAP, total plaque volume, puntaje de calcio progression). Confirm sustained achievement of lever targets; reinforce lifestyle adherence; address residual risk factors (Lp(a), if elevated, becomes a candidate for clinical-trial enrollment or emerging therapy if approved).
Long-term maintenance. Annual lipid and inflammatory biomarker monitoring; 2–3 year non-invasive imaging cycles; ongoing lifestyle reinforcement; vigilant management of metabolic comorbidities.

7.4 Special populations and individualization

Hipercolesterolemia familiar (heterozygous and homozygous). Heterozygous FH patients typically require maximally tolerated statin plus ezetimibe plus PCSK9 inhibitor from initial diagnosis, with ApoB-anchored escalation targets matching the recurrent-event tier. Homozygous FH (HoFH) patients require additional consideration of lomitapida (microsomal triglyceride transfer protein inhibition) or Aféresis de LDL, with evinacumab (anti-angiopoietin-like 3) emerging as a transformative option.

Statin intolerance. True statin-attributable myopathy is uncommon (≤5% in placebo-controlled n-of-1 designs), but functional intolerance is more frequent. Bempedoic acid plus ezetimibe provides a non-muscle-affecting backbone; PCSK9 inhibitors can be added for additional LDL reduction. The CLEAR Outcomes trial [16] established cardiovascular benefit in this population specifically.

Lp(a) elevada. Roughly 20% of the population has clinically actionable Lp(a) elevation (>50 mg/dL or >125 nmol/L). Until Lp(a)-directed therapies (pelacarsen, olpasiran) receive outcomes-validated approval, the operational response is intensified LDL/apoB lowering—pushing LDL-C below 55 mg/dL even in moderate-risk patients with elevated Lp(a), recognizing that LDL-C reduction does not address the Lp(a) burden itself but partially compensates by reducing total atherogenic particle exposure.

Post-ACS / recurrent-event patients. The PACMAN-AMI [11] and COLOCT [12] trials established that early, intensive lever-1 plus lever-2 targeting in the first weeks following acute coronary syndrome produces measurable plaque stabilization within 12 months. The recurrent-event tier targets should be operationalized within days of the index event.

Diabetes and metabolic syndrome. SGLT2 inhibitor plus GLP-1 receptor agonist deployment is now indication-driven, not lipid-driven, with substantial cardiovascular benefit independent of glycemic control [24,25,26]. The vascular benefits are additive to lipid-lowering and anti-inflammatory therapy.

8. Discussion

The evidence reviewed in the preceding sections supports a substantially revised conceptual model of coronary atherosclerosis: a chronic, multi-pathway inflammatory and metabolic disease whose progression is no longer biologically inevitable. Several features of this evidence base deserve focused discussion: the apparent disproportion between modest volumetric plaque regression and large reductions in hard clinical events; the operationalization of residual inflammatory risk; the methodological limitations of the imaging endpoints on which much of the regression literature rests; and the principal barriers—largely operational rather than biological—to widespread clinical deployment.

8.1 The volume-outcome paradox: composition over volume

A central observation of the serial-imaging literature is that the magnitudes of plaque volume regression achieved by intensive therapy—typically 1–3 percentage points of PAV reduction over 12–24 months—are quantitatively modest relative to the magnitudes of clinical event reduction (15–30% relative MACE reduction). REVERSAL [7] achieved virtually no PAV regression (essentially no progression vs. progression with pravastatin), yet the same lipid-lowering intensity translates into substantial event reduction in the outcomes trials [1,2,3]. GLAGOV [10] documented an absolute PAV reduction of approximately 1.0%, while FOURIER [3] documented a 20% reduction in the key secondary cardiovascular endpoint with the same therapy.

This apparent disproportion is not a paradox once plaque composition is integrated into the analysis. The clinical events that lipid-lowering and anti-inflammatory therapies prevent—ruptura de placa or erosion leading to myocardial infarction or muerte súbita cardíaca—depend not on total plaque volume but on the structural stability of the fibrous cap, the volume and inflammatory activity of the necrotic core, and the local composition of plaque calcification. A plaque that has undergone fibrous cap thickening from 60 µm to 100 µm (a clinically meaningful stabilization, as documented by PACMAN-AMI [11] and COLOCT [12]) is dramatically less likely to rupture, even if its total volume has decreased by only 1–2%. Conversely, a stable, large, densely calcified plaque is far less prone to rupture than a small, lipid-rich, thin-capped plaque of equivalent angiographic prominence.

The PARADIGM registry [44] explicitly captured this composition-over-volume dynamic at population scale: statin-treated patients showed slower progression of total plaque volume but accelerated conversion of non-calcified plaque (the rupture-prone substrate) to calcified plaque (the mechanically stable substrate). The clinical event reduction with statin therapy is therefore better understood as a structural composition shift than as a volume reduction per se. This reframing has significant implications for surrogate-endpoint selection in regression trials: PAV change remains a valid and reproducible endpoint, but it must be interpreted alongside composition metrics (low-attenuation plaque volume, fibrous cap thickness, lipid arc, necrotic core volume) for full mechanistic resolution.

8.2 Operationalizing residual inflammatory risk

The collaborative analysis by Ridker, Bhatt, and colleagues [43] established that residual inflammatory risk (on-statin hsCRP ≥2 mg/L) is a stronger predictor of recurrent events than residual cholesterol risk in patients with achieved LDL-C below 70 mg/dL. The clinical implication is that hsCRP measurement should be integrated into the standard follow-up algorithm for patients with established ASCVD, and that persistently elevated hsCRP should trigger consideration of anti-inflammatory therapy with low-dose colchicine.

Several caveats apply. First, hsCRP is a non-specific marker that rises in any inflammatory state—autoimmune disease, active infection, post-surgical recovery, malignancy. The 2-mg/L threshold for vascular inflammation requires exclusion of these factores de confusión. Second, hsCRP is the downstream output of an inflammatory cascade in which IL-1β, IL-6, and other cytokines are the actionable mediators; canakinumab directly targets IL-1β, while colchicine targets the upstream NLRP3 inflammasome. The choice of intervention is therefore not arbitrary: anti-NLRP3 strategies (colchicine) may be more broadly effective than narrow IL-1β neutralization for patients in whom the upstream activator of inflammation is uncertain.

Third, the optimal duration of anti-inflammatory therapy is not yet established. COLCOT [13] y LoDoCo2 [14] demonstrated benefit at 2–3 years; longer-term safety data are accumulating but remain limited. Colchicine pharmacokinetics, drug-interaction profile (particularly with strong CYP3A4 inhibitors and P-glycoprotein substrates), and renal/hepatic constraints require ongoing surveillance.

8.3 Clinical implementation barriers

Despite a strong evidence base, deployment of multi-pathway atherosclerosis regression therapy remains incomplete in real-world practice. Several barriers operate at distinct levels of the healthcare system.

Provider-level barriers. Generalist clinicians may underestimate the magnitude of additional benefit conferred by escalation beyond statin monotherapy, particularly in patients whose LDL-C is technically ‘controlled’ (below 100 mg/dL) but well above the levels demanded by recurrent-event risk tier. The substantial body of imaging and outcomes data supporting LDL-C targets of 30–40 mg/dL in secondary prevention is sometimes treated as aspirational rather than operational.

System-level barriers. Access to PCSK9 inhibitors, inclisiran, icosapent ethyl, and—in some jurisdictions—high-cost glucose-lowering agents with cardiovascular indications is constrained by formulary restrictions and prior-authorization requirements. The cost-effectiveness profiles of these agents, particularly for secondary prevention with documented benefit, are now strongly favorable; the operational frictions to access nevertheless remain a significant barrier.

Patient-level barriers. Adherence to multi-agent regimens, particularly when combined with the structural lifestyle changes (plant-forward dietary pattern, supervised exercise) that catalyze pharmacologic benefit, is challenging. The DISCO-CT data [35] are encouraging in this regard: even after substantial behavioral rebound, durable vascular biomarker improvement persists, suggesting that some elements of the lifestyle effect are encoded in vascular biology in a manner that outlasts the behavior.

Imaging access. Routine serial intravascular imaging is impractical for most patients. CCTA with AI-QCT analysis provides a non-invasive longitudinal-tracking modality that has been validated against IVUS and OCT [44,45], but access varies significantly by jurisdiction and is not yet uniformly reimbursed for serial monitoring outside research settings.

8.4 Limitations of the evidence base

Several methodological limitations of the cited evidence deserve explicit acknowledgment. The REDUCE-IT [6] mineral-oil placebo has been the subject of ongoing controversy: mineral oil may have produced modest adverse effects (small elevations in LDL-C, hsCRP, and biomarkers of inflammation) in the comparator arm, potentially exaggerating the apparent magnitude of IPE benefit. Although the prespecified analyses and the EVAPORATE [22] imaging data support IPE efficacy independent of placebo effects, the precise magnitude of the cardiovascular benefit warrants ongoing reassessment as evidence accumulates.

The Yellow III trial, which used serial OCT plus IVUS plus NIRS to evaluate evolocumab effects on plaque composition in statin-treated secondary-prevention patients, documented approximately 30% non-response at the fibrous-cap-thickness endpoint—a reminder that pharmacologic response is biologically heterogeneous and that statin/PCSK9-based regression strategies do not benefit all patients equivalently. Identifying the determinants of non-response (Lp(a) elevation, residual inflammation, dietary noncompliance, genetic variants in lipid handling, deeper metabolic dysfunction) is an important research priority.

The COLOCT [12] lipid arc reduction value (Δ ≈ −31°) cited in Section 6 is reported here as medium-confidence pending final cross-check against the primary publication’s tabulated values. The COLOCT minimum fibrous cap thickness change is more reproducibly documented as a clinically meaningful structural stabilization signature; the lipid arc component is presented as directionally consistent but warrants editorial verification.

Lifestyle Heart Trial [20,21] and Esselstyn-paradigm [36,50] data, while providing the only randomized evidence for lifestyle-only angiographic regression, are limited by small sample sizes, intensive supervised intervention conditions that may not generalize to real-world deployment, and—in the case-series literature—the absence of randomized control. The DISCO-CT [35] data are more contemporary and multicenter but use composition and biomarker endpoints rather than hard cardiovascular outcomes.

The Lp(a)-directed therapies (pelacarsen, olpasiran) have demonstrated profound molecular effects [18,19] but await outcomes-validation through Lp(a)HORIZON and OCEAN(a)-Outcomes. The inclisiran outcomes trial (ORION-4) is similarly pending. Recommendations for these agents in Section 7 are therefore mechanism-and-precedent-based rather than outcomes-validated, and clinicians should follow trial readouts as they emerge.

8.5 Future directions

Several research and clinical-translation priorities follow from the synthesis presented here:

Personalization of escalation. The biological heterogeneity of regression response (e.g., the ~30% non-responder fraction documented in Yellow III) argues for biomarker-guided escalation algorithms that integrate baseline lipoprotein particle composition, inflammatory markers, Lp(a), and—when available—imaging-derived composition metrics. The technology to perform such individualized algorithms exists; their formal validation in randomized comparative-effectiveness trials is a near-term opportunity.

Lp(a) outcomes validation. The Lp(a)HORIZON and OCEAN(a)-Outcomes trials are the most important pending readouts of the next several years. Positive trials would validate the first targeted therapy for a genetically determined atherogenic lipoprotein and would substantially extend the residual-risk framework.

Long-term safety of ultra-low LDL-C combined with anti-inflammatory therapy. The FOURIER open-label extension and the longer-term follow-up of CANTOS, COLCOT, and LoDoCo2 cohorts are providing the safety data necessary to confirm that ultra-low LDL-C achievement (<30 mg/dL) combined with anti-inflammatory therapy does not produce unanticipated long-term adverse effects. Preliminary data are reassuring but require ongoing surveillance.

Non-invasive serial imaging standardization. The AI-QCT validation literature [44,45] is mature, but standardization across vendor platforms, reimbursement frameworks, and quality-assurance protocols is uneven. Society-level standards documents, analogous to the Mintz IVUS standards [47] and Tearney OCT consensus [48], would accelerate routine clinical adoption of serial CCTA monitoring.

Implementation science. The largest opportunity to reduce population-level cardiovascular mortality is now not the discovery of new molecules but the systematic deployment of existing, validated multi-pathway therapy. Implementation science—addressing provider education, formulary access, patient adherence, and integrated lifestyle support—is, in operational terms, the principal lever remaining.

9. Conclusion

Atherosclerosis is now a measurably reversible disease. The mechanistic foundation—the apoB-particle retention hypothesis [28,29,30]—is well established. The dose-response relationship between achieved apoB and event reduction is log-linear and ceiling-free across the clinically achievable range [1,2]. Serial intravascular and non-invasive imaging trials have documented plaque regression, fibrous cap thickening, necrotic core depletion, and the conversion of rupture-prone non-calcified plaque to mechanically stable calcified plaque under intensive multi-pathway therapy [7–12, 22, 44]. Outcomes trials of statins, PCSK9 inhibitors, ezetimibe, bempedoic acid, icosapent ethyl, canakinumab, colchicine, SGLT2 inhibitors, and GLP-1 receptor agonists have collectively reduced cardiovascular events by 15–30% per intervention, with effects that are additive when deployed in combination.

The volume-outcome paradox—wherein 1–3% reductions in plaque volume yield 15–30% reductions in clinical events—is mechanistically resolved by structural plaque stabilization rather than by volumetric reduction per se. Regression is an active biological process: it requires phenotypic switching of intimal macrophages from inflammatory M1/M4 phenotypes toward resolving M2/Mhem/Trem2⁺ phenotypes, sustained reduction in apoB-particle entry below the rate of intimal lipid efflux, and suppression of inflammasome-driven fibrous cap degradation. The pharmacologic and lifestyle interventions that achieve regression are those that drive this biology in a coordinated, multi-axis fashion.

The clinical evidence supports a five-lever framework (Section 7): apoB-particle reduction to risk-tier-matched ultra-low targets; inflammatory pathway inhibition via low-dose colchicine in patients with residual hsCRP elevation; triglyceride-rich-lipoprotein and membrane stabilization via icosapent ethyl in eligible patients; metabolic-axis modulation via SGLT2 inhibitors and GLP-1 receptor agonists in patients with diabetes or metabolic syndrome; and lifestyle reinforcement through plant-forward dietary patterns, structured aerobic exercise, and smoking cessation. Deployed coordinately, this framework converts vulnerable plaques into quiescent, fibrosed, micro-calcified lesions that resist rupture.

The remaining barriers to widespread reversal of atherosclerosis at the population level are not biological. They are operational: provider familiarity with intensive multi-pathway escalation; formulary access to non-statin lipid-lowering, anti-inflammatory, and metabolic agents; patient adherence to multi-agent and lifestyle regimens; and reimbursement frameworks for serial non-invasive plaque-composition imaging. Closing these operational gaps—not the discovery of new molecules—is now the principal lever available to reduce cardiovascular mortality further.

The implication for clinical practice is that coronary atherosclerosis, in the year 2026, should no longer be regarded as a disease whose progression is inevitable and whose acute consequences are merely managed. It is a disease whose underlying biology can be arrested and structurally reversed, with measurable changes at the level of the arterial wall, in the great majority of patients to whom modern, deliberate, multi-pathway therapy is applied.

Acknowledgments and Disclosures

This narrative review was prepared by the author independently for the educational platform Curing Heart Disease (curingheartdisease.com). The author reports no commercial conflicts of interest and has received no financiamiento de la industria for the preparation of this manuscript. The platform does not sell supplements, devices, or paywalled content; all editorial recommendations reflect synthesis of the cited peer-reviewed literature.

AI-assisted tools were used in the drafting and editorial production of this manuscript. All cited values, references, and clinical claims have been traced to primary publications; three medium-confidence values (the Yellow III non-responder fraction, the COLOCT lipid arc reduction in degrees, and the PARADIGM annual non-calcified plaque progression rate) are flagged in the methods (Section 2.3) as warranting editorial verification against primary-source PDFs prior to formal publication submission.

Referencias

References are presented in IEEE numeric format in the order of first appearance in the text. Abstract-only retrievals during the review window are flagged [Abstract Verified]; full-text retrievals are otherwise the basis of cited values.

Nota de transparencia: Esta entrada de blog fue creada con la asistencia de herramientas de inteligencia artificial. El contenido final ha sido cuidadosamente revisado y editado por el autor, quien es responsable de su precisión. La información proporcionada es únicamente para fines educativos y no constituye consejo médico.